University of Kentucky

UKnowledge
Pharmaceutical Sciences Faculty Patents

Pharmaceutical Sciences

2-19-2019

Eis Inhibitors
Sylvie Garneau-Tsodikova
University of Kentucky, sylviegtsodikova@uky.edu

Oleg V. Tsodikov
University of Kentucky, oleg.tsodikov@uky.edu

James E. Posey

Follow this and additional works at: https://uknowledge.uky.edu/ps_patents
Part of the Chemicals and Drugs Commons, and the Pharmacy and Pharmaceutical Sciences
Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Recommended Citation
Garneau-Tsodikova, Sylvie; Tsodikov, Oleg V.; and Posey, James E., "Eis Inhibitors" (2019). Pharmaceutical
Sciences Faculty Patents. 180.
https://uknowledge.uky.edu/ps_patents/180

This Patent is brought to you for free and open access by the Pharmaceutical Sciences at UKnowledge. It has been
accepted for inclusion in Pharmaceutical Sciences Faculty Patents by an authorized administrator of UKnowledge.
For more information, please contact UKnowledge@lsv.uky.edu.

IIIIII IIIIIIII Ill lllll lllll lllll lllll lllll lllll lllll lllll 111111111111111111
USO 10208000B2

c12)

United States Patent

(IO)

Garneau-Tsodikova et al.

(45)

(56)

(54)

EIS INHIBITORS

(71)

Applicants:University of Kentucky Research
Foundation, Lexington, KY (US); The
United States of America, as
represented by the Secretary,
Department of Health and Human
Services, Rockville, MD (US)

(72)

(73)

Inventors: Sylvie Garneau-Tsodikova, Lexington,
KY (US); Oleg V. Tsodikov, Lexington,
KY (US); James E. Posey, Rockville,
MD (US)
Assignee: University of Kentucky Research
Foundation, Lexington, KY (US)

( *)

Notice:

(21)

Appl. No.: 15/381,901

(22)

Filed:

(65)

Subject to any disclaimer, the term ofthis
patent is extended or adjusted under 35
U.S.C. 154(b) by O days.

Dec. 16, 2016
Prior Publication Data

US 2017/0174639 Al

Jun. 22, 2017

Related U.S. Application Data
(60)

Provisional application No. 62/268,244, filed on Dec.
16, 2015.

(51)

Int. Cl.
(2006.01)
C07D 241/44
(2006.01)
A61K 31/498
(2006.01)
A61K 31/7036
(2006.01)
A61K 45/06
U.S. Cl.
CPC .......... C07D 241/44 (2013.01); A61K 31/498
(2013.01); A61K 31/7036 (2013.01); A61K
45/06 (2013.01)
Field of Classification Search
CPC .................................................... C07D 241/44
See application file for complete search history.

(52)

( 58)

Patent No.:
US 10,208,000 B2
Date of Patent:
Feb.19,2019
References Cited
U.S. PATENT DOCUMENTS

5,852,016
5,912,245
6,096,744
8,642,660

A
12/1998 Faye et al.
A
6/1999 Riv6 et al.
A
8/2000 Kornberg et al.
B2 * 2/2014 Goldfarb.

9,108,953 B2
2009/0163545 Al*

8/2015 Babaoglu et al.
6/2009 Goldfarb.

A61K 31/122
514/18.9
A61K 31/122
514/312

FOREIGN PATENT DOCUMENTS
WO

W02015/080707

6/2015

OTHER PUBLICATIONS
Olayiowla, G. et al., Synthesis and neuropharrnacological activity of
some quinoxalinone derivatives African Journal of Biotechnology
(2007), 6(6), 777-786 CODEN: AJBFAH; ISSN: 1684-5315 URL:
http://www.academicjournals.org/ AJB/PDF/pdf2007 /l 9Mar/
Olayiwola%20et%20al.pd f; English.*
Garzan, et al., Sulfonamide-Based Inhibitors of Aminoglycoside
Acetyltransferase Eis Abolish Resistance to Kanamycin in
Mycobacterium tuberculosis; J. Med. Chem. 2016, 59, 1061910628.
Garzan, et al., Supporting Information for Sulfonamide-Based Inhibitors of Aminoglycoside Acetyltransferase Eis Abolish Resistance to
Kanarnycin in Mycobacterium tuberculosis; J. Med. Chem. 2016,
59, Sl-S9.

* cited by examiner
Primary Examiner - Paul V Ward
(74) Attorney, Agent, or Firm - Mandy Wilson Decker;
Stites & Harbison PLLC

(57)
ABSTRACT
Provided herein are novel small-molecules that have use in
the inhibition of Eis, which mediates kanamycin resistance
in Mycobacterium tuberculosis. The presently-disclosed
subject matter further includes a pharmaceutical composition including a small molecule inhibitor, as described
herein, and a suitable pharmaceutical carrier. Methods of
treating tuberculosis comprising administering to an individual an effective amount of the disclosed small molecule
inhibitors to mediate kanamycin A resistance and treat
tuberculosis are also provided.
16 Claims, 5 Drawing Sheets
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EIS INHIBITORS

Multiacetylation by Eis has a defined pattern for each AG:
the number of acetylations and the positions of the amino
groups that get acetylated depend on the structure of the AG.
Furthermore, Eis homologues from Mycobacterium smegmatis, Mycobacterium abscessus, Anabaena variabilis,
Bacillus anthracis, Gordonia bronchialis, Kocuria rhizophila (9), and Tsukamurella paurometabola are also functional AACs, which exhibit differences in regiospecificity
and can be inhibited by chlorhexidine, a non-clinically
relevant Eis_Mtb inhibitor. In addition to AG substrate
versatility, Eis enzymes display some acyl-CoAco-substrate
promiscuity and can acetylate non-AG molecules containing
lysine residues, such as capreomycin and the JNK-specific
dual-specificity protein phosphatase 16 (DUSP16)/mitogenactivated protein kinase phosphatase-7 (MKP-7) pair. These
observations underscore the uniqueness and versatility of
Eis AG modifying activity and its high capacity for inactivation of diverse AG drugs.
The development of AGs that cannot be modified by Eis
or a novel therapy that would involve an Eis inhibitor used
in combination with KAN are two possible approaches to
resolve the need in the field of drug resistant tuberculosis.
The former route is complicated by the ability of Eis to
accept structurally diverse AGs as substrates, whereas the
latter route is potentially more suitable. The latter approach
to combat drug resistance arising as a result of drugmodifying enzymes, then, is to use a combination therapy
that includes an antibiotic along with an inhibitor of its
associated resistance enzyme. In Mtb, including MDR TB,
the combination of the ~-lactamase inhibitor clavulanate and
the ~-lactam meropenem was demonstrated to overcome
resistance to ~-lactam antibiotics. With this strategy in mind,
efforts have also been made towards identifying inhibitors of
aminoglycoside acetyltransferases (AACs) present in nonmycobacteria, with limited pre-clinical progress, but these
are not applicable for the mechanistically and structurally
distinct Mtb Eis acetyltransferase. For example, aminoglycoside-acetyl coenzyme A bi-substrate inhibitors were found
to potently inhibit AAC(6') enzymes in vitro, but were not
effective in cell-based assays. Numerous cationic peptides
that inhibit AAC(6') enzymes in vitro were identified, but
these also displayed no antibacterial effects against resistant
bacterial strains due to membrane permeability issues.
Finally, the natural product aranorosin was found to be an
inhibitor of the bi-functional AAC(6')-Ie/APH(2")-Ia
enzyme, and its combination with the aminoglycoside
arbekacin was shown to stop the growth of a methicillinresistant Staphylococcus aureus strain.
We previously reported that some Eis inhibitors displayed
AG-competitive and mixed modes of action, establishing a
proof of principle for inhibition of Eis in vitro.
A two-drug combination therapy where one drug targets
an offending cell and the other targets a resistance mechanism to the first drug is a time-tested, yet underexploited
approach to combat or prevent drug resistance in an infectious disease. Furthermore, there remains a need for
approaches to combat drug resistant TB.

RELATED APPLICATIONS
This application claims priority from U.S. Provisional
Application Ser. No. 62/268,244, filed Dec. 16, 2015, the
entire disclosure of which is incorporated herein by this
reference.
GOVERNMENT INTEREST
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This invention was made with govermnent support under
National Institutes of Health (NIH) Grant AI090048. The
govermnent has certain rights in the invention.
15

TECHNICAL FIELD
The presently-disclosed subject matter relates to compositions useful as inhibitors of acetyltransferase Eis, a mediator ofkanamycin resistance in Mycobacterium tuberculosis,
and their methods of use. In particular, the compositions are
sulfonamide-based and sulfonyl isothiazole-based small
molecules.
INTRODUCTION
A major cause of tuberculosis (TB) resistance to the
aminoglycoside kanamycin (KAN) is the Mycobacterium
tuberculosis (Mtb) acetyltransferase Eis. Eis is a superacetyltransferase from M. tuberculosis that inactivates all
clinically used aminoglycosides. Upregulation of Eis is a
frequent cause of clinical resistance to the aminoglycoside
kanamycin (KAN) in TB. Upregulation of this enzyme is
responsible for inactivation of KAN through acetylation of
its amino groups.
Tuberculosis (TB) is an infectious disease caused by
Mycobacterium tuberculosis (Mtb ), and a major global
health threat. In 2013, approximately 9.0 million people
developed TB, and nearly 1.5 million died from the disease.
Due to the spread of multidrug-resistant TB (MDR TB),
defined as TB with resistance to at least isoniazid and
rifampin (-10% of new TB cases in 2013) and extensively
drug-resistant TB (XDR TB), defined as MDR TB with
added resistance to at least a fluoroquinolone and an injectable drug (i.e., kanamycin (KAN), capreomycin, or amikacin), the need for novel strategies to combat drug resistant
TB is urgent.
The aminoglycosides (AGs) kanamycin A (KAN) and
amikacin (AMK) are used to treat MDR- and XDR-TB, but
resistance to these agents occurs as well. Among mechanisms of clinically important transmissible drug resistance is
the recently identified inactivation of an MDR-TB therapeutic, the aminoglycoside kanamycin, through its acetylation
by an upregulated acety ltransferase, the Eis (enhanced intracellular survival) enzyme. We previously demonstrated that
the Mtb Eis protein (Eis_Mtb) is an acetyltransferase
capable of multiacetylating a variety of AGs, including the
TB therapeutics KAN and AMK, via a random sequential
mechanism, thereby abolishing the antibiotic activity of
these drugs. The ability of acetylating an AG molecule at
multiple amine positions due to its unique structure distinguishes Eis from other AG acetyltransferases (AACs),
which are known to be exquisitely regiospecific. A crystal
structure of Eis_Mtb in complex with coenzyme A and
tobramycin demonstrated how tobramycin could interact
with the Eis active site in two binding modes for the
observed diacetylation of the 6'- and 3"-amines of this AG.
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The presently-disclosed subject matter meets some or all
of the above-identified needs, as will become evident to
those of ordinary skill in the art after a study of information
provided in this document.
This summary describes several embodiments of the
presently-disclosed subject matter, and in many cases lists
variations and permutations of these embodiments. This
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summary is merely exemplary of the numerous and varied
embodiments. Mention of one or more representative features of a given embodiment is likewise exemplary. Such an
embodiment can typically exist with or without the
feature(s) mentioned; likewise, those features can be applied
to other embodiments of the presently-disclosed subject
matter, whether listed in this summary or not. To avoid
excessive repetition, this summary does not list or suggest
all possible combinations of such features.
The presently-disclosed subject matter includes compositions useful as inhibitors of acetyltransferase Eis, a mediator ofkanamycin resistance in Mycobacterium tuberculosis,
and their methods of use. In particular, the compositions are
sulfonamide-based and sulfonyl isothiazole-based small
molecules. In some embodiments, the inhibitors can effectively overcome kanamycin resistance in strains of Mtb.
In some embodiments, the compositions are a compound
of the formula:

In some embodiments, the compounds are included in a
pharmaceutical composition. In some embodiments, the
pharmaceutical composition includes the compounds of the
present invention and a suitable pharmaceutical carrier. In
some embodiments, compositions and pharmaceutical compositions include the small molecule compounds set forth
herein, such as for example, the compounds in Tables 18, 4
and 5, a suitable pharmaceutical carrier, and an aminoglycoside. In some embodiments, the aminoglycoside is
kanamycin (KAN).
Methods of using the Eis inhibitors are also disclosed. In
some embodiments, methods of inhibiting Eis include
administering an effective amount of a composition including the compounds disclosed herein, including those set
forth in Tables 18, 4, or 5 is disclosed. In some embodiments, such methods include administration of a compound
selected from compounds 29, 30, 32-35, 37-39, 41, 43, and
46 in Table 18.
In some embodiments, the compound is according to the
formula:
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In some embodiments, the compounds is of the formula of
any one of compounds 33-47, as set forth in Table 18 herein.

65

wherein the Rl and R2 groups are according to the structures
identified in Table 5 as 3i, 6b, 7b, Sa, Se, Ile, 12e, 13a, 13e,
13g, 13i, 14c, 15e, 15f, 17i, 33a, 35e, 35g, 35h, 35i, 36d,
37b, 37d, 46a, 46b, 46c, 46h, 52i, 62i, 81 b, Sig, 87b, 89b,
112b, 112i, 115i, 116i, 139b, 139e, and 139i. In some
embodiments, Eis inhibition is effectuated by administration
of the disclosed compounds.
In one aspect, the administration of the disclosed compound yields a Minimal Inhibitory ConcentrationKanamycin
(MICKANJ value is less than about 2.5 µg/mL to about 5
µg/mL to a Mtb strain. In some embodiments, the MIC level
is reduced to a level close to a KAN-susceptible Mtb strain,
and can be characterized as fully overcoming kanamycin
resistance. In some embodiments, the IC 50 , that is, the
concentration of an inhibitor's Eis inhibitory activity is
increased. In some embodiments, the IC 50 is about 0.08 µM
to about 0.25 µM against purified Eis enzyme, in other
embodiments, the IC 50 is less than about 0.25 µM.
Methods of administration can include, in some embodiments, administering an aminoglycoside or a combination of
drugs including an aminoglycoside. In some embodiments,
the aminoglycoside is kanamycin (KAN).
Methods of treating aminoglycoside-resistant Mycobacterium tuberculosis are also disclosed and include administering the compounds of the present invention, including
compounds as set forth in Tables 18, 4 and 5. In some
embodiments, such methods of treatment include administering an aminoglycoside, before, during or after treatment
with the compounds of the present invention. In some
embodiments, the aminoglycoside is administered with a
combination of other active drugs. In some instances, the
aminoglycoside is kanamycin (KAN). In one aspect, the
methods of treatment include administering the aminoglycoside and presently-disclosed compounds to a subject in
need of treatment for aminoglycoside-resistant Mtb.
A kit including the compounds as disclosed herein, for
example, a compound as set forth in Tables 18, 4 and 5,

US 10,208,000 B2
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packaged together with an aminoglycoside are also disclosed. In some embodiments, the kit contains the aminoglycoside kanamycin.

present invention(s). Each example is provided by way of
explanation of the present disclosure and is not a limitation
thereon. In fact, it will be apparent to those skilled in the art
that various modifications and variations can be made to the
teachings of the present disclosure without departing from
the scope of the disclosure. For instance, features illustrated
or described as part of one embodiment can be used with
another embodiment to yield a still further embodiment.
All references to singular characteristics or limitations of
the present disclosure shall include the corresponding plural
characteristic(s) or limitation(s) and vice versa, unless otherwise specified or clearly implied to the contrary by the
context in which the reference is made.
All combinations of method or process steps as used
herein can be performed in any order, unless otherwise
specified or clearly implied to the contrary by the context in
which the referenced combination is made.
The presently-disclosed subject matter includes compounds that are useful for inhibiting Eis. In some embodiments, the compound has the following structure:

BRIEF DESCRIPTION OF THE DRAWINGS

5

The novel features of the subject matter of the present
disclosure are set forth with particularity in the following
description and in the appended sample claims. A better
understanding of the features and advantages of the pres- 10
ently disclosed subject matter will be obtained by reference
to the following detailed description that sets forth illustrative embodiments, in which the principles of the
invention(s) are used, and the accompanying drawings.
FIG. 1 shows representative dose response curves for 15
sulfonamide inhibitors of the present invention with pure
Eis.
FIG. 2 is a cartoon view of the crystal structure of Eis in
complex with compound 39 and CoA. FIG. 2a. provides the
overall view of a monomer of Eis-CoA-inhibitor 39 com- 20
plex; FIG. 2b. provides the zoomed-in view of the AGbinding site with the bound inhibitor. The omit F 0 -F c map
(contoured at 3a) generated without the inhibitor is shown as
0
mesh. The bound CoA is omitted to avoid obstructing the
view. The inhibitor is shown as sticks and the interacting 25
side chains of Eis are shown as pale sticks.
R,
N
II
FIG. 3 is a schematic representation of the winnowing of
a
-123,000 small organic molecules to 18 showing inhibition
#
N
O
H
,
of both Eis enzymatic activity and growth of Mtb K204 in
30
the presence of KAN.
FIG. 4 provides crystal structures of EisC204A from Mtb
where R is defined as set forth in Table 18, hereinbelow. In
in complex with 13g (a and b) and l le (c and d). The overall
some embodiments, the compound is any one of compounds
views of the Eis monomer with the inhibitors bound (a and
33-47, as set forth in Table 18. In some embodiments, the
c) and zoom-in views of the active site (band d) show that
compound has the following structure:
the inhibitors occupy a site overlapping with the AG sub- 35
strate-binding site. The F 0 -F c omit map contoured at 3a is
shown by the mesh. Inhibitor interacting residues are shown
as sticks. Water molecules mediating inhibitor binding are
shown as navy blue spheres. The side chain of Asp26 and the
backbone of this residue and its neighbors adopt different 40
conformations in the two complexes. The CoAmolecule was
observed in the same position as in previously reported
structures, with the phosphopantetheinyl arm exhibiting
disorder and is not shown for the sake of clarity.
FIG. 5 includes representative IC 50 plots for the inhibition 45 where R 1 and R 2 are defined as set forth in Tables 4 and 5.
of Eis using fresh powder for several of the inhibitors
The presently-disclosed subject matter also includes comidentified in Table 5.
positions comprising one or more of compounds as set forth
in Table 18. In some embodiments, the composition
DESCRIPTION OF EXEMPLARY
includes one or more of compounds 33-47, as set forth in
EMBODIMENTS
50
Table 18. In some embodiments, the composition includes
one or more compounds as set forth in Tables 18, 4, and 5.
The details of one or more embodiments of the presentlyIn some embodiments, the composition includes one or
disclosed subject matter are set forth in this document.
more compounds identified in Table 5 as 3i, 6b, 7b, Sa, Se,
Modifications to embodiments described in this document,
Ile, 12e, 13a, 13e, 13g, 13i, 14c, 15e, 15f, 17i, 33a, 35e,
and other embodiments, will be evident to those of ordinary 55
35g, 35h, 35i, 36d, 37b, 37d, 46a, 46b, 46c, 46h, 52i, 62i,
skill in the art after a study of the information provided in
Sib, Sig, 87b, 89b, 112b, 112i, 115i, 116i, 139b, 139e, and
this document. The information provided in this document,
139i. In some embodiments, the composition is a pharmaand particularly the specific details of the described exemceutical composition further comprising a pharmaceuticallyplary embodiments, is provided primarily for clearness of
understanding and no unnecessary limitations are to be 60 acceptable carrier.
The presently-disclosed subject matter further includes
understood therefrom. In case of conflict, the specification of
methods or inhibiting Eis and methods of treating aminothis document, including definitions, will control.
glycoside-resistant Mtb. In some embodiments the method
The presently-disclosed subject matter is illustrated by
involves administering a compound or composition as disspecific but non-limiting examples throughout this description. The examples may include compilations of data that are 65 closed herein. In some embodiments, the method involves
representative of data gathered at various times during the
administering a compound or composition to a subject in
course of development and experimentation related to the
need of treatment for aminoglycoside-resistant Mtb. In some

I

/~U~XO
I
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embodiments, the method further includes administering an
aminoglycoside. In some embodiments the aminoglycoside
is kanamycin (KAN).
The terms "treat," "treatment," and the like refer to the
medical management of a subject with the intent to cure,
ameliorate, stabilize, or prevent a disease, pathological condition, or disorder. This term includes active treatment, that
is, treatment directed specifically toward the improvement
of a disease, pathological condition, or disorder, and also
includes causal treatment, that is, treatment directed toward
removal of the cause of the associated disease, pathological
condition, or disorder. In addition, this term includes palliative treatment, that is, treatment designed for the relief of
symptoms rather than the curing of the disease, pathological
condition, or disorder; preventative (prophylatic) treatment,
that is, treatment directed to minimizing or partially or
completely inhibiting the development of the associated
disease, pathological condition, or disorder; and supportive
treatment, that is, treatment employed to supplement another
specific therapy directed toward the improvement of the
associated disease, pathological condition, or disorder.
In some embodiments, a method is provided for treating
antibiotic resistance and/or inhibiting Eis enzymatic activity
in a cell. In some embodiment the method includes contacting the cell with compounds disclosed herein. The term
"contacting" as used herein refers to any means by which the
compound is brought into sufficient proximity and/or in
direct contact with a cell such that the cell is capable of
receiving the compound. For instance, in some embodiments
contact refers to coating or otherwise exposing a cell to the
compound. In some embodiments contact refers to culturing
a cell in a solution that includes the compound. In other
embodiments the cell is within a subject, and contact refers
to administering a compound to the subject such that a cell
within the subject is capable of receiving the novel small
molecule compounds. In some embodiments, such methods
can include further administration of an antibiotic at the
same time as the administration of the compound, or prior to
or subsequent to the administration of compound. In some
embodiments, the antibiotic is kanamycin. The presentlydisclosed subject matter further includes composition that
include at least one compound disclosed herein as an Eis
inhibitor, and an aminoglycoside. In some embodiments the
aminoglycoside is kanamycin (KAN). In some embodiments, the cell exhibits resistance to kanamycin. In some
embodiments, said cell is within a subject diagnosed with
tuberculosis.
The presently-disclosed subject matter further includes
kits comprising at least one compound disclosed herein as an
Eis inhibitor, packaged together with an aminoglycoside. In
some embodiments the aminoglycoside is kanamycin
(KAN).
The presently disclosed subject matter includes identified
potent inhibitors of Eis enzymatic activity with resulting
sensitization of KAN-resistant Mtb cells, in which the
resistance to KAN is caused by Eis upregulation. The
inhibitors bind in the AG binding pocket blocking the access
of AGs to the active site of the enzyme. The inhibitor
binding is accompanied by induced-fit conformational
changes of the protein. These compounds have a great
potential for further development as KAN adjuvants in Mtb.
The presently-disclosed subject matter includes novel
small molecule compositions, and small molecule compositions useful as inhibitors of Eis enzymatic activity. In some
instances, the small molecule is a sulfonamide-based structure. In some embodiments, the small molecule is a sulfonyl

isothiazole-based composition. In some embodiments, the
inhibitors can effectively overcome kanamycin resistance in
strains of Mtb.
In one aspect, the administration of the disclosed compound yields a Minimal Inhibitory ConcentrationKanamycin
(MICKANJ value is less than about 2.5 µg/mL for Mtb strains.
In some embodiments, the MICKAN is less than about 0.625
µg/mL for Mycobacterium tuberculosis (Mtb) strain H37Rv,
or less than about 5 µg/mL for Mtb strain K204. In some
embodiments, the MIC level is reduced to a level close to a
KAN-susceptible Mtb strain, and can be characterized as
fully overcoming kanamycin resistance. For example, in
Mtb strain K204, a measured MICKAN of less than or equal
to 1.25 µg/mL would indicate a compound with inhibitory
activity sufficient to overcome kanamycin resistance. As
such, in some embodiments, the KAN MIC values of a
compound are expressed as a 2-fold, four fold, 8-fold or
more reduction in KAN MIC against a Mtb strain.
In some embodiments, the IC 50 , the concentration of an
inhibitor's Eis inhibitory activity is measured. In some
embodiments, the IC 50 is about 0.08 µM to about 0.25 µM
against purified Eis enzyme. However, as one skilled in the
art will recognize, compounds can reduce the MIC value of
a KAN-resistant Mtb strain with IC 50 values that vary
according to how measured. For example, in vitro measurements differ from those values measured in cellulo or in
vivo. For example, IC 50 values ranging from 0.1 to about
4.35 µM when measured in cellulo or in vivo can be
indicative of an effective Eis inhibitor, as these activities are
not exactly correlated. Such variances can be for a wide
variety of reasons, including, for example, based upon
difficulty of small molecules penetrating the waxy cell wall
of Mycobacteria.
Methods of treating kanamycin resistance are also disclosed herein, comprising administering a small molecule
composition disclosed herein. Also provided are methods of
treating tuberculosis comprising administering the Eis
inhibitors disclosed herein with kanamycin. The presentlydisclosed subject matter further includes a pharmaceutical
composition including a small molecule, as described
herein, and a suitable pharmaceutical carrier. The presentlydisclosed subject matter also includes a method of treating
a bacterial infection comprising administering to an individual an effective amount of a small molecule Eis inhibitor,
as disclosed herein. In some instances, the pharmaceutical
composition is administered with an aminoglycoside. In
some instances the aminoglycoside is Kanamycin.
While the following terms used herein are believed to be
well understood by one of ordinary skill in the art, definitions are set forth to facilitate explanation of the presentlydisclosed subject matter.
The terms "polypeptide", "protein", and "peptide", which
are used interchangeably herein, refer to a polymer of the
protein amino acids, or amino acid analogs, regardless of its
size or function. Although "protein" is often used in reference to relatively large polypeptides, and "peptide" is often
used in reference to small polypeptides, usage of these terms
in the art overlaps and varies. The term "polypeptide" as
used herein refers to peptides, polypeptides, and proteins,
unless otherwise noted. The terms "protein", "polypeptide",
and "peptide" are used interchangeably herein when referring to a gene product. Thus, exemplary polypeptides
include gene products, naturally occurring proteins,
homologs, orthologs, paralogs, fragments and other equivalents, variants, and analogs of the foregoing.
Unless otherwise indicated, the term "administering" is
inclusive of all means known to those of ordinary skill in the
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art for providing a preparation to a subject, including administration by inhalation, nasal administration, topical administration, intravaginal administration, ophthalmic administration,
intraaural
administration,
intracerebral
administration, intravitreous administration, intracameral
administration, posterior sub-Tenon administration, posterior juxtascleral administration, subretinal administration,
suprachoroidal administration, cell-based administration or
production, rectal administration, and parenteral administration, including injectable such as intravenous administration, intra-arterial administration, intramuscular administration, and/or subcutaneous administration. Administration
can be continuous or intermittent. A preparation can be
administered therapeutically; that is, administered to treat an
existing condition of interest. A preparation can be administered prophylactically; that is, administered for prevention
of a condition of interest.
In some embodiments a subject will be administered an
effective amount of at least one compound and/or composition provided in the present disclosure. In this respect, the
term "effective amount" refers to an amount that is sufficient
to achieve the desired result or to have an effect on an
undesired condition. For example, a "therapeutically effective amount" refers to an amount that is sufficient to achieve
the desired therapeutic result or to have an effect on undesired symptoms, but is generally insufficient to cause
adverse side effects. The specific therapeutically effective
dose level for any particular patient will depend upon a
variety of factors including the disorder being treated and
the severity of the disorder; the specific composition
employed; the age, body weight, general health, sex and diet
of the patient; the time of administration; the route of
administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used
in combination or coincidental with the specific compound
employed and like factors well known in the medical arts.
For example, it is well within the skill of the art to start doses
of a compound at levels lower than those required to achieve
the desired therapeutic effect and to gradually increase the
dosage until the desired effect is achieved. If desired, the
effective daily dose can be divided into multiple doses for
purposes of administration. Consequently, single dose compositions can contain such amounts or submultiples thereof
to make up the daily dose. The dosage can be adjusted by the
individual physician in the event of any contraindications.
Dosage can vary, and can be administered in one or more
dose administrations daily, for one or several days. Guidance
can be found in the literature for appropriate dosages for
given classes of pharmaceutical products. In further various
aspects, a preparation can be administered in a "prophylactically effective amount"; that is, an amount effective for
prevention of a disease or condition.
Additionally, the terms "subject" or "subject in need
thereof' refer to a target of administration, which optionally
displays symptoms related to a particular disease, pathological condition, disorder, or the like. The subject of the herein
disclosed methods can be a vertebrate, such as a mammal, a
fish, a bird, a reptile, or an amphibian. Thus, the subject of
the herein disclosed methods can be a human, non-human
primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea
pig or rodent. The term does not denote a particular age or
sex. Thus, adult and newborn subjects, as well as fetuses,
whether male or female, are intended to be covered. A
patient refers to a subject afflicted with a disease or disorder.
The term "subject" includes human and veterinary subjects.

In some embodiments the subject in need thereof will be
suffering or will have been diagnosed tuberculosis and/or
related diseases, disorders, pathologies, or conditions.
As used herein, the terms "treatment" or "treating" relate
to any treatment of a condition of interest, including but not
limited to prophylactic treatment and therapeutic treatment.
As such, the terms treatment or treating include, but are not
limited to: preventing a condition of interest or the development of a condition of interest; inhibiting the progression
of a condition of interest; arresting or preventing the development of a condition of interest; reducing the severity of a
condition of interest; ameliorating or relieving symptoms
associated with a condition of interest; and causing a regression of the condition of interest or one or more of the
symptoms associated with the condition of interest.
Unless defined otherwise, all technical and scientific
terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which the
presently-disclosed subject matter belongs. Although any
methods, devices, and materials similar or equivalent to
those described herein can be used in the practice or testing
of the presently-disclosed subject matter, representative
methods, devices, and materials are now described.
Following long-standing patent law convention, the terms
"a", "an", and "the" refer to "one or more" when used in this
application, including the claims. Thus, for example, reference to "an enzyme" includes a plurality of such enzymes,
and so forth.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions,
and so forth used in the specification and claims are to be
understood as being modified in all instances by the term
"about". Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this specification and
claims are approximations that can vary depending upon the
desired properties sought to be obtained by the presentlydisclosed subject matter.
As used herein, the term "about," when referring to a
value or to an amount of mass, weight, time, volume,
concentration or percentage is meant to encompass variations of in some embodiments ±50%, in some embodiments
±40%, in some embodiments ±30%, in some embodiments
±20%, in some embodiments ±10%, in some embodiments
±5%, in some embodiments ±1 %, in some embodiments
±0.5%, and in some embodiments ±0.1 % from the specified
amount, as such variations are appropriate to perform the
disclosed method.
As used herein, ranges can be expressed as from "about"
one particular value, and/or to "about" another particular
value. It is also understood that there are a number of values
disclosed herein, and that each value is also herein disclosed
as "about" that particular value in addition to the value itself.
For example, if the value "10" is disclosed, then "about 10"
is also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, if 10
and 15 are disclosed, then 11, 12, 13, and 14 are also
disclosed.
As will be recognized by one of ordinary skill in the art,
the terms "reduce", "reducer", "reduction", "reducing",
"suppression," "suppressing," "suppressor," "inhibition,"
"inhibiting" or "inhibitor" do not refer to a complete elimination of angiogenesis in all cases. Rather, the skilled artisan
will understand that the term "reducing", "suppressing" or
"inhibiting" refers to a reduction or decrease in a particular
condition. Such reduction or decrease can be determined
relative to a control. In some embodiments, the reduction or
decrease relative to a control can be about a 1, 2, 3, 4, 5, 6,

10

15

20

25

30

35

40

45

50

55

60

65

US 10,208,000 B2
11

12

7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,
24,25, 26,27,28, 29, 30,31,32, 33,34,35,36, 37,38,39,
40,41, 42,43,44, 45, 46,47,48, 49, 50, 51, 52, 53, 54, 55,
56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71,
72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87,
88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%
decrease.
As described herein, the presently-disclosed subject matter further includes pharmaceutical compositions comprising at least one enzyme described herein together with a
pharmaceutically acceptable carrier.
The term "pharmaceutically acceptable carrier" refers to
sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just
prior to use. Proper fluidity can be maintained, for example,
by the use of coating materials such as lecithin, by the
maintenance of the required particle size in the case of
dispersions and by the use of surfactants. These compositions can also contain adjuvants such as preservatives,
wetting agents, emulsifying agents and dispersing agents.
Prevention of the action of microorganisms can be ensured
by the inclusion of various antibacterial and antifungal
agents such as paraben, chlorobutanol, phenol, sorbic acid
and the like. It can also be desirable to include isotonic
agents such as sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can
be brought about by the inclusion of agents, such as aluminum monostearate and gelatin, which delay absorption.
Injectable depot forms are made by forming microencapsule
matrices of the drug in biodegradable polymers such as
polylactide-polyglycolide, poly(orthoesters) and poly(anhydrides ). Depending upon the ratio of drug to polymer and the
nature of the particular polymer employed, the rate of drug
release can be controlled. Depot injectable formulations are
also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues. The
injectable formulations can be sterilized, for example, by
filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water
or other sterile injectable media just prior to use. Suitable
inert carriers can include sugars such as lactose.
Suitable formulations include aqueous and non-aqueous
sterile injection solutions that can contain antioxidants,
buffers, bacteriostats, bactericidal antibiotics and solutes
that render the formulation isotonic with the bodily fluids of
the intended recipient; and aqueous and non-aqueous sterile
suspensions, which can include suspending agents and
thickening agents.
The compositions can take such forms as suspensions,
solutions or emulsions in oily or aqueous vehicles, and can
contain formulatory agents such as suspending, stabilizing
and/or dispersing agents. Alternatively, the active ingredient
can be in powder form for constitution with a suitable
vehicle, e.g., sterile pyrogen-free water, before use.
The formulations can be presented in unit-dose or multidose containers, for example sealed ampoules and vials, and
can be stored in a frozen or freeze-dried (lyophilized)
condition requiring only the addition of sterile liquid carrier
immediately prior to use.
For oral administration, the compositions can take the
form of, for example, tablets or capsules prepared by a
conventional technique with pharmaceutically acceptable
excipients such as binding agents (e.g., pregelatinized maize
starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or

calcium hydrogen phosphate); lubricants (e.g., magnesium
stearate, talc or silica); disintegrants (e.g., potato starch or
sodium starch glycolate); or wetting agents (e.g., sodium
lauryl sulphate). The tablets can be coated by methods
known in the art.
Liquid preparations for oral administration can take the
form of, for example, solutions, syrups or suspensions, or
they can be presented as a dry product for constitution with
water or other suitable vehicle before use. Such liquid
preparations can be prepared by conventional techniques
with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or
hydrogenated edible fats); emulsifying agents (e.g. lecithin
or acacia); non-aqueous vehicles (e.g., almond oil, oily
esters, ethyl alcohol or fractionated vegetable oils); and
preservatives (e.g., methyl or propyl-p-hydroxybenzoates or
sorbic acid). The preparations can also contain buffer salts,
flavoring, coloring and sweetening agents as appropriate.
Preparations for oral administration can be suitably formulated to give controlled release of the active compound. For
buccal administration the compositions can take the form of
tablets or lozenges formulated in conventional manner.
The compositions can be formulated as eye drops. For
example, the pharmaceutically acceptable carrier may comprise saline solution or other substances used to formulate
eye drop, optionally with other agents. Thus, eye drop
formulations permit for topical administration directly to the
eye of a subject.
The compositions can also be formulated as a preparation
for implantation or injection. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil)
or ion exchange resins, or as sparingly soluble derivatives
(e.g., as a sparingly soluble salt). The compounds can also
be formulated in rectal compositions, creams or lotions, or
transdermal patches.
The presently-disclosed subject matter further includes a
kit that can include an enzyme and/or a pharmaceutical
composition as described herein, packaged together with a
device useful for administration of the compound or composition. As will be recognized by those or ordinary skill in
the art, the appropriate administration-aiding device will
depend on the formulation of the compound or composition
that is selected and/or the desired administration site. For
example, if the formulation of the compound or composition
is appropriate for injection in a subject, the device could be
a syringe. For another example, if the desired administration
site is cell culture media, the device could be a sterile
pipette.
The presently-disclosed subject matter includes novel
small molecules. Also disclosed are small molecules that
inhibit Eis. Small molecule Eis inhibitors disclosed herein
aid in reducing KAN resistance and/or restoring KAN
susceptibility in Mycobacterium tuberculosis. The presently-disclosed subject matter further includes a pharmaceutical composition including a small molecule inhibitor, as
described herein, and a suitable pharmaceutical carrier,
optionally administered with Kanamycin. The presentlydisclosed subject matter further includes a method of treating tuberculosis, including aminoglycoside resistant tuberculosis, comprising administering to an individual an
effective amount of a small molecule Eis inhibitor, as
disclosed herein, to inhibit the Eis acetyltransferase of
Mycobacterium tuberculosis and reduce KAN resistance
and/or restore KAN susceptibility.
In certain embodiments, the present disclosure further
provides a method of treating, preventing and/or reducing
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kanamycin resistance and/or restoring KAN susceptibility in
Mycobacterium tuberculosis. The method comprises at least
the step of administering an effective amount of a small
molecule inhibitor provided in the present disclosure to a
subject. In some embodiments, the subject is in need of
treatment. In some instances, the Mycobacterium tuberculosis strain is Mtb K204 or H137Rv. In some embodiments,
the small molecule is administered with an aminoglycoside,
for example, kanamycin. In some embodiments, the treatment reduces and/or eliminates the Eis-mediated KAN resistance of Mycobacterium tuberculosis.
Additionally, in certain embodiments, the inhibitors of the
present disclosure have a Mtb strain K204 Minimal Inhibitory ConcentrationKanamycin (MICKAN) value of less than
about 5.0 µg/mL, of less than about 2.5 µg/mL, or less than
about 1.25 µg/mL. In other embodiments, the inhibitors have
a MICKAN value of less than about 0.625 µg/mL for Mycobacterium tuberculosis (Mtb) strain H37Rv.
The presently-disclosed subject matter is illustrated by the
following specific but non-limiting examples. The following
examples may include compilations of data that are representative of data gathered at various times during the course
of development and experimentation related to the present
invention.

These Eis inhibitors are useful for the pre-clinical development of innovative AG combination therapies against resistant TB.
Identification and Chemical Synthesis of Eis Inhibitors.
To identify potential Eis inhibitor candidates, over 123,
000 structurally diverse small molecules were screened by
an established UV absorbance-based HTS assay (12) for
their inhibition of KAN acetylation by the Eis_Mtb acetyltransferase in vitro. The screening of this molecular library
against Eis_Mtb led to the identification of a sulfonamide
scaffold (Table 18). The HTS library contained 29 compounds (1-29) with this core structure, and four of them (1-3
and 29) were identified as hits (i.e., compounds
displaying ;;,;3-fold inhibition than the standard deviation
( calculated for the inert compounds at 20 µM)). Compounds
4-28 were found not to inhibit Eis in the HTS. However,
compounds 1-3 displayed some Eis inhibition and compound 29 potently inhibited Eis activity (IC 50 =0.5±0.1 µM).
Based on this encouraging result, compound 29 along with
18 additional sulfonamide analogues (30-47) containing a
variety of substituents on the aniline ring to define a preliminary body of structure-activity relationship (SAR) of Eis
inhibition were freshly synthesized. The compounds evaluated in this work were synthesized according to the synthetic
pathway described in Table IA. In the first step, which is
common to all compounds, 2,3-dihydroxyquinoxaline was
reacted with chlorosulfonic acid and the resulting sulfonyl
chloride was then reacted with different aniline derivatives
to obtain compounds 29-47.
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EXAMPLES
The discovery and rational structure-based optimization
via medicinal chemistry of promising Eis inhibitors that not
only efficiently inhibit the purified enzyme, but also restore
KAN susceptibility of KAN-resistant Mtb are reported
herein. Also reported is a crystal structure of Eis in complex
with CoA and one potent sulfonamide inhibitor, which
reveals its mode of action, explaining the SAR study and
provides for further rational structure-based development of
Eis inhibitors.
The inventors of the present invention set out to identify
inhibitors of Eis that could be co-administered with KAN in
order to prevent inactivation by Eis in Mtb. Herein the
identification as well as the biochemical and biological
characterization of several potent inhibitors of Eis are
reported that were able to restore the antibacterial activity of
KAN in a KAN-resistant strain, Mtb K204. To clarify in
atomic details the mode of action of these compounds and
their structure-activity-relationships, crystal structures of
EisC204A in complex with CoA and two of these inhibitors
were also determined.
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TABLE 2-continued

A. Synthetic scheme used for the preparation of the molecules generated
in this study. B. Structures of molecules used in this study.

IC 50 values against purified Eis and MIC values against Mtb
H37Rv and Mtb K204.

Compound#
46: R~

10

OMe

47:R~

~-ca

15

20

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

ICso (µM)"
10.6 ± 2.5
5.8 ± 1.8
0.100 ± 0.045
0.25 ± 0.06
>200
3.0 ± 0.7
0.056 ± 0.004
5.8 ± 1.2
7.4 ± 3.3
0.37 ± 0.09
0.027 ± 0.012
0.23 ± 0.03
0.7 ± 0.3
27 ± 8
0.00024 ± 0.00010
0.30 ± 0.08

H37Rv MIC KAN K204 MIC KAN
(µg/mL)"
(µg/mLl
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25
,;1.25

2.5
2.5-5
10
2.5
,;1.25
5-10
2.5-5
5-10
2.5-5
5-10
5-10
,;1.25
10

aIC 50 values against purified Eis enzyme,
banti-TB activity of KAN against Mtb H37Rv,
canti-TB activity of KAN against Mtb K204.
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Biochemical and Biological Testing of Sulfonamides
29-47.
To investigate the potential of these compounds as Eis
inhibitors for use in combination with KAN, their biochemical (IC 50 values against purified Eis enzyme) and biological
(effect on the MIC values of KAN in KAN-sensitive Mtb
H37Rv and in Mtb K204, which is KAN-resistant due to Eis
upregulation properties were evaluated in parallel studies
(Table 2 and FIG. 1). The freshly synthesized compound 29
displayed robust inhibition of Eis in vitro (IC 50 =0.08±0.02
µM). When combined with KAN, sulfonamide 29, resulted
in a four-fold reduced KAN MIC value (2.5 µg/mL) compared to KAN alone (10 µg/mL) for K204 Mtb. This was a
reduction almost to the MIC level of KAN in the KANsusceptible Mtb H37Rv (1.25 µg/mL) parent strain. To gain
insight into the importance of the substitution pattern on the
aniline portion of the sulfonamide scaffold, secondary
(NHAr) and tertiary (N(Me)Ar) sulfonamides (29-47) were
first generated. Eis inhibition assays with the synthesized
sulfonamides were carried out in combination with KAN.
The non-methylated counterpart oflead compound 29, compound 30, displayed lower Eis inhibitory activity
(IC 50 =6.24±1.31 µM) and, contrary to 29, did not overcome
KAN resistance in Mtb K204 (MICKAN=lO µg/mL). Two
other non-methylated derivatives, 31 and 32, also resulted in
lower Eis inhibitory activity (IC 50 >200 and 10.6±2.5 µM,
respectively) and did not overcome KAN resistance in Mtb
K204 (MICKAN=lO and 5 µg/mL, respectively). These data,
in conjunction with the fact that compounds 1-12 from the
HTS did not display significant Eis inhibition, suggest that
the N-methyl group is essential for efficient Eis inhibition
and antitubercular activity.
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TABLE 2
IC 50 values against purified Eis and MIC values against Mtb
H37Rv and Mtb K204.

Compound#

29
30
31

ICso (µM)"

0.08 ± 0.02
6.2 ± 1.3
>200

60

H37Rv MICKAN K204 MICKAN
(µg/mL)"
(µg/mLl
1.25
,;1.25
,;1.25
,;1.25

10
2.5
65
10

Having established the importance of the N-methyl moiety, the effect of substitutions on the benzene ring of the
aniline moiety were explored. Removing all substituents on
the benzene ring (compound 33) resulted in a 70-fold
decrease in Eis inhibitory activity (IC 50 =5.8±1.8 µM) when
compared to that of lead 29 and did not overcome KAN
resistance in Mtb K204, suggesting the importance of a
substituted aniline for Eis inhibition and antitubercular
activity. In general, para substitution (compounds 29 with a
p-Br, 34 with a p-Cl, and 35 with a p-iPr) was found to be
highly favorable and yielded compounds with IC 50 values
varying from 0.08-0.25 µM, which overcame KAN resistance (MICKAN=2.5 µg/mL) in KAN-resistant Mtb. Interestingly, p-methoxy substitution resulted in a compound (13)
that was found to be inactive during our HTS. To delineate
if ortho or meta substitution would be even more favorable
than para substitution, we generated compounds 36 (with an
o-OMe) and 39 (with a m-OMe ). The o-methoxy substituted
36 was found to be completely inactive (IC 50 >200 µM and
MICKAN=lO µg/mL against Mtb K204), whereas the
m-methoxy substituted 39 was found to be a potent Eis
inhibitor (IC 50 =5.8±1.2 µM) and was one of our two compounds to fully overcome KAN resistance in Mtb K204
(MICKANsl .25 µg/mL). It is important to note that incorporating an additional m-methoxy group, as in compound 40,
was detrimental for the overall activity of the molecule,
which suggested that mono-substitution is more promising
than di-substitution. We also synthesized the m-bromo
derivative 38, which demonstrated a slightly improved Eis
inhibitory activity (IC 50 =0.056±0.004 µM) than did the
corresponding para derivative 29, while also being able to
overcome KAN resistance in Mtb K204 (MIC=2.5 µg/mL).
We also found that the m-iso-propyl derivative 43 and its
para counterpart 35 displayed similar Eis inhibitory activity
(IC 50 =0.23±0.03 and 0.25±0.06 µM, respectively) and
resulted in identical KAN MIC values (2.5-5n/mL) against
KAN-resistant Mtb. While the p-methyl derivative 14 was
inactive in our HTS, its meta counterpart 41 displayed good
Eis inhibition (IC 50 =0.37±0.09 µM) and some ability to
overcome KAN resistance in Mtb K204 (MIC 2.5-5 µg/mL).
These data suggest that mono-mew substitution is either
equal or more advantageous then para, which is more
beneficial than ortho. Based on these results, we generated
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additional m-alkylated sulfonamides (42, 44, and 45) and
observed that longer or bulkier alkyl groups, although good
for Eis inhibition, did not produce compounds capable of
overcoming KAN resistance in Mtb K204. Finally, with the
hope of increasing any possible Jt-Jt interaction between the
inhibitor and the AG-binding site of the Mtb Eis, we
generated compound 46, which showed an incredible
increase in Eis inhibitory activity (IC 50 =0.00024±0.00010
µM) and was found to completely overcome KAN resistance
in Mtb K204 (MICKANsl.25 µg/mL). Compound 46 is
currently our most potent and promising Eis inhibitor that
can be used in conjunction with KAN.
To examine the selectivity of our two best inhibitors (39
and 46) towards Eis, next these two compounds were tested
against three other AAC enzymes: AAC(2')-Ic from Mtb
(17, 18), AAC(3)-IV from E. coli (19, 20), and AAC(6')-Ie/
APH(2")-Ia from Staphylococcus aureus (21, 22). Sulfonamides 39 and 46 did not inhibit KAN acetylation by the
AACs tested at concentrations as high as 200 µM with the
exception of 39, which inhibited 15% of the AAC(2')-Ic
activity when tested at 200 µM. These data demonstrate the
high selectivity of the inhibitors towards Eis.
Crystal Structure of EisC204A-CoA-inhibitor 39 Complex. In order to characterize the mechanism of our Eis
inhibitors, explain the SAR, and aid in future drug development, the crystal structure of Eis in complex with CoA
and inhibitor 39 was determined at the resolution of 2.1 A
(FIG. 2 and Table 3).

aniline moiety is stacked between the rings of Phe84 and
Trp36, with the methoxy group surrounded by the nonpolar
stem oftheArg37 side chain, Phe84, Trp13, and Val40. This
explains why removing the aniline ring resulted in a loss of
activity for compounds 12, 15, 16, and 22-26. The quinoxaline moiety stacks against Phe24, a residue that interacts
with tobramycin, as previously observed in a crystal structure of an Eis-TOB complex. The NH group of the quinoxaline ring on the side of the sulfonamide forms a hydrogen
bond with the carboxyl group of Asp26 (N---0 distance of
2.9 A) and the oxygen of the sulfonamide forms a hydrogen
bond with the main chain nitrogen of Ile28 (0-N distance
of3.0 A). Our SAR studies showed that compounds with an
N-methyl group of the sulfonamide moiety displayed higher
Eis inhibitory activity than those with an NH group, which
can be rationalized by the optimal van der Waals interaction
of the methyl with Trp36 (the distance between the methyl
C atom and the closest C of the Trp36 side chain is 3.6 A).
Eliminating the methyl group would abolish this interaction,
putting a polar NH in a hydrophobic environment, likely
destabilizing binding (5 vs 37, 30 vs 29, 31 vs 33, and 32 vs
35). Replacing the aniline ring with an N-aryl piperazine
(compounds 17-21) resulted in a loss of Eis inhibitory
activity when compared to the aniline ring. As described
above, this part of the molecule is snugly fit in a hydrophobic
pocket, which is too small to accommodate these larger
groups. The ortho position of the aniline ring is flanked by
the C-terminal residue Phe402 and it abuts Phe84, explaining why an ortho substitution, as in compound 36, resulted
in a loss of Eis inhibitory activity. A bulky group such as
n-butyl (44) or t-butyl (45) in meta position of the aniline
ring would clash with Arg3 7 that is structurally fixed by Jt-Jt
stacking with the inhibitor, explaining the poor inhibitory
activity of these two compounds. A meta,meta-disubstitution
( 40) resulted in a dramatic decrease in activity as the second
substituent would clash with the side chain of Met65.
Electron-donating groups such as methoxy (39) or a naphthalene ring (46) increase the Jt-Jt interaction of the aniline
ring with Phe84 and Trp36, explaining their stronger interactions in the AG-binding pocket of Eis. However, combining the two substituents in compound 47 led to a loss of
activity, as both substitutions cannot be sterically accommodated.
The overall conformation of Eis in complex with the
inhibitor is similar to the previously reported crystal structure. A notable conformational difference is that a part of a
loop (residues 28-30) and a helix (residues 31-37) are shifted
towards the inhibitor relative to their conformation in the
structure without the inhibitor by 1-1.5 A, apparently in an
induced-fit fashion, to maximize steric contacts. The indole
ring ofTrp36 in this helix is rotated by -40°, maximizing the
stacking with the aniline ring and other interactions, as
explained above. These small, but significant conformational changes likely precluded us from obtaining a correct
model of a bound inhibitor by prior extensive computational
docking simulations. In summary, the crystal structure of the
EisC204A-CoA-inhibitor 39 complex allowed explanation
of biochemical and biological data and provides a solid
foundation for further rational structure-based development
of Eis inhibitors.
In conclusion, the biochemical, biological, and structural
studies described in this example provide a proof-of-principle of the activity of Eis inhibitors as promising KAN
adjuvants. The SAR combined with the co-crystal structure
will guide future development of these compounds for their
clinical use against MDR- and XDR-TB.
Synthesis and Characterization of Sulfonamides 29-47.
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TABLE 3
X-ray diffraction data collection and refinement statistics
for the EisC204A-CoA-inhibitor 39 ternary complex structure.
Data collection

35
Space group
Number of monomers per asymmetric unit
Unit cell dimensions
a, b, c (A)
13, y ( 0 )
Resolution (A)
Ila
Completeness (%)
Redundancy

a,

Rmerge

Number of unique reflections
Structure refinement statistics
Resolution (A)
R(%)
Rfree (%)
Bond length deviation (rmsd) from ideal
(A)
Bond angle deviation (rmsd) from ideal ( 0 )
Ramachandran plot statisticsb
%
%
%
%

of residues
of residues
of residues
of residues

in
in
in
in

most allowed regions
additional allowed regions
generously allowed regions
disallowed regions

R32

175.2, 175.2, 122.3
90, 90, 120
50.0-2.1 (2.14-2.10)"
16 (2.1)
95.8 (97.7)
3.9 (3.8)
0.08 (0.50)
37,907

40.0-2.1
19.4
21.9
0.006

40

45

50

1.35

93.8
6.2
0.0
0.0 (0 residues)

55

aNumbers in parentheses indicate the values in the highest-resolution shell.
bindicates Procheck statistics (23).

Although sulfonamide 46 was the best compound in
biochemical and biological studies, it did not co-crystallize
with Eis. Therefore efforts were focused on compound 39,
the second best compound. The crystal structure demonstrates that inhibitor 39 is bound in the part of the AGbinding pocket that is formed by the N-terminal domain of
Eis. The inhibitor is apparently stabilized in the bound state
by numerous hydrophobic interactions. Specifically, the

60

65
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Sulfonamides 29-47 were synthesized in two chemical
steps (Table IA). A detailed description of the synthetic
procedures as well as characterization by 1 H, 13 C NMR, and
mass spectrometry can be found in the Materials and Methods Section.
5
Chemical Library Screening for Eis Inhibitors, Hit Validation, Inhibition Kinetics, and Inhibitor Selectivity.
Acetyltransferase inhibition was assessed by monitoring
the absorbance at 412 nm (E 412 =14140 M- 1 cm- 1 ) of a
compound generated by the reaction between the free thiol 10
group ofCoAreleased during acetylation and 5',5-dithiobis(2-nitrobenzoic acid) (DTNB), as described in the Materials
and Methods and Table 2.
Mycobacterial MIC Determination by Alamar Blue.
The MIC values for KAN in the absence and presence of 15
Eis inhibitors 29-47 was determined against KAN-sensitive
and KAN-resistant Mtb strains H37Rv and K204, respectively, as described in detailed in the Materials and Methods
Section and Table 2.
Crystallization and Structure Determination of the 20
EisC204A-CoA-Inhibitor 39 Complex.
Inhibitor 39 was soaked into rhombohedral crystals of
EisC204A in complex with CoA upon an elaborate solvent
exchange procedure as described in details in the Materials
and Methods. Data were collected and the structure was 25
determined by molecular replacement using the previously
published Eis structure (PDB code 3R1K) as the initial
model. The inhibitor was built unambiguously into a strong
F 0 -F c electron density as detailed in the Materials and
30
Methods, FIG. 2, and Table 3.

were re-tested (Table 4 and Table 5). Of these 617 molecules, 133 showed reproducible inhibition of Eis enzymatic
activity in the same single-point HTS assay. Thirty-six of
these 133 compounds were chosen for further testing in
dose-response assays, based on the potency of their inhibition of Eis in the HTS assay and the structural diversity of
their chemical substituents (R 1 and R 2 groups). In a previous
study of Eis inhibitors evaluating fewer molecules, we
demonstrated that active compounds contained (i) a group
that may become positively charged, usually an amine, or
(ii) an aromatic group. The presence of either of these groups
was therefore also a criterion for selection of compounds for
dose-response testing. Additionally, four analogues that
were not a part of the original library were included, but
which contained the same structural core (Table 4). This
process yielded a group of forty molecules, for which IC 50
values were determined against purified Eis. The effect of
these compounds on KAN MIC for KAN-susceptible
(H37Rv) and KAN-resistant (K204) Mtb strains (Table 5),
were also measured as described in the two following
sections.
TABLE 4
Structures of Compounds of Example 2.
The 617 molecules tested are noted in Table 6.

Example 2
Disclosed herein are inhibitors of Eis that could be
co-administered with KAN in order to prevent inactivation
by Eis in Mtb. Here, the identification as well as the
biochemical and biological characterization of several
potent inhibitors of Eis that were able to restore the antibacterial activity of KAN in a KAN-resistant strain, Mtb
K204 are reported. To clarify in atomic details the mode of
action of these compounds and their structure-activity-relationships, crystal structures of EisC204A in complex with
CoA and two of these inhibitors were also determined. A
123,000-compound high-throughput screen (HTS) yielded
several small-molecule Eis inhibitors that share a sulfonyl
isothiazole scaffold. These were investigated for their structure-activity relationships. Crystal structures of Eis in complex with two potent inhibitors show that these molecules
are bound in the conformationally adaptable aminoglycoside
binding site of the enzyme, thereby obstructing binding of
KAN for acetylation. Importantly, several Eis inhibitors,
when used in combination with KAN against resistant Mtb,
efficiently overcome KAN resistance. This approach paves
the way toward development of novel combination therapies
against aminoglycoside-resistant TB.
High-Throughput Screening Leads to the Identification of
a Promising Eis Inhibitor Scaffold.
In order to identify Mtb Eis inhibitors, HTS of molecular
libraries comprising 123,000 structurally diverse small molecules using a previously reported Eis acetylation assay in
the miniaturized format was performed (FIG. 3). The initial
HTS assay was performed using the aminoglycoside neomycin B (NEO) as a substrate, which was selected over
KAN to maximize the signal to noise ratio under the HTS
conditions. However, KAN was used in all post-HTS assays,
since it is the clinically relevant aminoglycoside. The HTS
yielded 617 hits containing a sulfonyl isothiazole core that
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against strains H36Rv and K204 Mtb have been evaluated

191:
192:
193:
194:
195:
196:
197:
198:

W - Cl, X - OCH 3
W - X - OCH 3
W, X - OCH2 0
W-Y- CH 3
W - Y - C02 CH 3
W - Y - OCH 3
V - X - Z - CH 3
V - OCH 3 , X - Cl, Y - CH 3

f

10

TABLE 5

15

g
(YCl

Structures of the 41 Eis inhibitors with sulofnyl scaffold
for which IC 50 against pure Eis enzyme and MIC values
against strains H36Rv and K204 Mtb have been evaluated
20

2C
h

25

Main
scaffold

2
F

a 30

35
b

40

Cl
45

50
d

55

e 60

65

sx-t()

,x-tp

sx-t(~
nx-tNCo

US 10,208,000 B2
41

42

TABLE 5-continued

TABLE 5-continued

Structures of the 41 Eis inhibitors with sulofnyl scaffold
for which IC 50 against pure Eis enzyme and MIC values
against strains H36Rv and K204 Mtb have been evaluated

Structures of the 41 Eis inhibitors with sulofnyl scaffold
for which IC 50 against pure Eis enzyme and MIC values
against strains H36Rv and K204 Mtb have been evaluated

UX-r-No
nx-t()
c,x-t(),;x-t{:)_/
nx-t()-0

15

20

25

81: X

~

Y

~

CH2CH3

30

33:

x~
35
Y~H

87:X~

35:

x~
40

36:

89:X~

x~
45

139: X

~

~o
~
(CH2)oCH3, Y

~

, Y~H

H

50

55

<SY-t()

s,v-k~

60

Inhibitors with IC 50 & MIC: 3i, 6b, 7b, 8a, 8e, llc, 12e, 13a, 13e, 13g, 13i, 14c, 15e, 15f,
17i, 33a, 35e, 35g, 35h, 35i, 36d, 37b, 37d, 46a, 46b, 46c, 46h, 52i, 62i, 81 b, 81g, 87b,
89b, 112b, 112i, 115i, 116i, 139b, 139e, 139i

Structure-Activity Relationship (SAR) Studies.
65

Various R 1 and R 2 side-chains in the identified sulfonyl
isothiazole scaffold (Tables 4-6), were explored to improve
anti-Eis potency in vitro.

us

10,208,000 B2

43

44

Based on the 617 initial HTS hit molecules, we first drew
several unambiguous conclusions about the desirable structure of the R 2 side-chain. Most of the compounds for which
R 2 contained an aromatic ring, a branched alkyl group, a

cyclohexyl moiety, or a benzyl functionality did not efficiently inhibit Mtb Eis. Table 6 is a summary of Eis activity
of compounds tested against enzyme and, in some instances,
Mtb.
TABLE 6

Eis activity of compounds tested against purified enzyme and/or Mtb.
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Eis activity of compounds tested against purified enzyme and/or Mtb.
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Symbol legend:
Empty box indicates that the combination of R 1 (letter) and R 2 (number) did not exist in the tested library.
x indicates that the compound did not inhibit Eis purified enzyme in the initial HTS.

D-- indicates that the

compound inhibited Eis purified enzyme in the initial HTS, but was not pursued for determination of IC 50 values.

Dxx indicates that the compound inhibited Eis purified enzyme in the initial HTS, but was found to not be a strong Eis inhibitor after determination
of its IC 50 and also did not affect Mtb growth.

DDx indicates that the compound inhibited Eis purified enzyme in the initial HTS and was found to be a moderate to good Eis inhibitor after
determination of its IC 50 , but did not affect Mtb growth.

DOD indicates that the compound inhibited Eis purified enzyme in the initial HTS and was found to be a moderate to good Eis inhibitor after
determination of its IC 50 , and was also found to affect Mtb growth.
DODD indicates compounds that we selected to purchase that were not in our initial HTS. These compounds were found to be a moderate to good
Eis inhibitor after determination of its IC50 and were also found to affect Mtb growth.

Compounds that did not efficiently inhibit Mtb Eis are
indicated by x in Table 6. Among the forty compounds that
were pursued beyond the dose-response assay, compounds
containing R 2 groups 8, 13, 15, 35, 46, and 81 inhibited Eis
in vitro when combined with multiple R 1 substituents (as
indicated by DDx and DOD, respectively, in Table 6) while
other R 2 groups were shown to inhibit Eis in dose-response
assays when in combination with only one of the possible R 1
substituents (6b, 7b, llc, 12e, 14c, 17i, 33a, 36d, 37b, 52i,
62i, and 112i). Overall, two large families ofR2 substituents
emerged as potential potent inhibitors of Eis: (i) compounds
with R 2 containing two nitrogen atoms separated by three
carbon atoms (structures 3, 6-8, 11-15, and 17), particularly
compounds with large bulky groups or a cyclohexyl ring
attached to the extended nitrogen atom were most often
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inhibitory; and (ii) compounds containing an R 2 group with
two nitrogen atoms separated by two carbon atoms also
efficiently inhibited Eis (structures 33, 35-37, and 112). In
this series of molecules, only compounds with a nitrogen
atom located in a cyclohexyl ring were inhibitory.
We next explored the effect of the R 1 substituents on Eis
inhibition. Upon initial inspection of the 617 HTS hits, the
identity of the R 1 substituent appeared to have little effect on
their Eis inhibitory activity. However, when analyzing these
side chains statistically, patterns emerged. The p-fluorophenyl group (b) had the highest percentage (34%) of compounds inhibiting Eis in the initial HTS; this was followed
closely by the p-methylphenyl group (e, 33%) and the
m,p-dimethylphenyl group (i, 30%), suggesting that these
three groups as R 1 substitutions have a better chance of
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contributing positively to Eis inhibition. The next best R 1
substituent was the p-chlorophenyl group (c) with 27% of
the compounds within this group displaying inhibition of
Eis. The m-chlorophoenyl group (g) and p-anisole group (d)
were next with 19% and 18% of their compounds displaying
Eis inhibition, respectively. Finally, with 13%, 12%, and 9%
of compounds showing Eis inhibition were compounds
containing the p-isopropylphenyl (f), the m-bromophenyl
(h), and the phenyl (a) group as Ri, respectively.
Having established general trends for the R 1 and R 2
substituents by analyzing the data from Table 6, we next
focused on the measured in vitro potency (IC 50 ) of the forty
selected compounds (Table 7).
Several trends consistent with those established above
emerged from these quantitative data. With the exception of
compound 112i, mono-substituted R 2 amine substituents
comprised of a straight alkyl chain (139b, 139e, 139i), an
aromatic ring (87b, 89b, 112b ), or an amide functionality
(115i, 116i) did not inhibit purified Eis. Compounds with R 2
substituents containing a diamine separated by two carbon
atoms with the second amine present in a cyclohexyl ring all
displayed good to moderate Eis inhibition. However, no
conclusion could be formed as to what type of cyclohexyl
ring was best, an unsubstituted (33a), a morpholino (35e, g,
h, and i), or a piperazinyl (36d or 37b) ring, as most IC 50
values were similar for these compounds. Compound 13i
with a diamine separated by three carbons at the R 2 position
and the m,p-dimethylphenyl group at the R 1 position was
found to be the most potent Eis inhibitor (IC 50 =0.054±0.002
µM). Interestingly, compound 46b with a cyclohexyl ring
directly attached to the core scaffold followed by a second
piperazine ring in the para-position was found to be the
second best Eis inhibitor (IC 50 =0.092±0.021 µM). These
results indicate that both a rotationally free alkyl chain (as in
compound 13i) or cyclically restricted alkyl linkers could be
useful in designing Mtb Eis inhibitors.

TABLE 7-continued
Eis inhibition IC 50 values of tested compounds and
tbe effect of tbe compounds on kanamycin A MIC values
against H37Rv and K204 Mtb strains.

Cpd
46c
10 46h
52i
62i
81b
81g
87b
89b
15
112b
112i
115i
116i
139b
139e
20 139i

25

30

35

Cpd

3i
6b
7b
Sa
Se
11c
12e
13a
13e
13g
13i
14c
15e
15f
17i
33a
35e
35g
35h
35i
36d
37b
37d
46a
46b

IC 50 (µM)"
0.120 ± 0.035
0.152 ± 0.045
0.102 ± 0.034
2.85 ± 0.26
0.200 ± 0.036
0.238 ± 0.089
0.183 ± 0.043
2.82 ± 0.21
0.331 ± 0.071
0.234 ± 0.060
0.054 ± 0.002
0.112 ± 0.008
0.535 ± 0.045
0.148 ± 0.016
0.232 ± 0.038
0.123 ± 0.023
>200
2.49 ± 0.49
3.23 ± 0.99
0.985 ± 0.190
0.152 ± 0.031
0.657 ± 0.105
>200
0.432 ± 0.057
0.092 ± 0.021

40

Concentration
tested (µM/

H37Rv
MIC KAN
(µg/mL)"

K204
MIC KAN
(µg/mLl

12
15.2
10.2
184.5
20
23.8
18.3
282.3
33.1
23.4
5.42
11.2
53.5
14.8
23.2
13.2
20
100
100
98.5
15.3
65.7
20
43.2
9.21

1.25
0.625
0.625
0.625
0.625-1.25
0.625
0.625
0.625
0.625
0.625
0.625
0.625
0.625
0.625-1.25
0.625-1.25
0.625-1.25
0.625
0.625
0.625
0.625
0.625
0.625
0.625
0.625-1.25
0.625-1.25
0.625-1.25

10
1.25
2.5
2.5
2.5-5
1.25
2.5
2.5
2.5
2.5-5
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2.5
2.5
2.5
2.5-5
2.5-5
5-10
10

H37Rv
MIC KAN
(µg/mL)"

K204
MIC KAN
(µg/mLl

10.9
13.5
58
38.6
124.8
142.3
20
20
20
62.1
20
20
20
20
20

0.625
0.625
0.625
0.625
0.625
0.625
1.25
1.25
0.625
0.625
0.625
1.25
0.625
1.25
1.25

2.5
2.5
2.5-5
2.5
10
10
10
10
10
10
10
10

aTbe IC50 values in the Eis acetyltransferase assay.
bAt these concentrations, these compounds did not inhibit the growth ofH37Rv or that of
K204 Mtb, when tested in the absence of KAN.
"KAN MIC values for H37Rv Mtb in the absence (first line) and in the presence of each
compound at the specified concentrations.
dSame as c, but for K204 Mtb.

To establish whether the inhibitors identified were specific
to Eis over AACs from other families, compounds 46b and
46c were tested against AAC(6')-Ie/APH(2")-Ia from
Staphylococcus aureus, AAC(3)-IV from E. coli, and AAC
(2')-Ic from Mtb. Under optimal reaction conditions for each
enzyme, no inhibition by either compound was observed
with any of these AACs. These data demonstrate that the
compounds are exquisitely selective for Mtb Eis over other
AACs.
Eis Inhibitors Abolish Eis-Mediated Resistance of Mtb to
KAN.

TABLE 7
Eis inhibition IC 50 values of tested compounds and
tbe effect of tbe compounds on kanamycin A MIC values
against H37Rv and K204 Mtb strains.

ICso (µM)"
0.109 ± 0.022
0.135 ± 0.031
0.580 ± 0.096
0.386 ± 0.080
1.25 ± 0.22
1.42 ± 0.42
>200
>200
>200
0.621 ± 0.229
>200
>200
>200
>200
>200

Concentration
tested (µM/
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Having identified inhibitors of purified Mtb Eis enzyme,
we next set to determine their activity in cellulo. Mycobacteria are notorious for their waxy cell wall that is difficult to
penetrate for small molecules. Therefore, we anticipated that
not all of the compounds that exhibited inhibition of purified
Eis would be effective in cell cultures. We measured the
effect of the forty selected compounds (at a concentration of
100-fold higher than their IC 50 values) on KAN MIC values
against Mtb K204, a KAN-resistant strain bearing a clinically observed eis promoter mutation known to upregulate
Eis production (Table 7). In the KAN-susceptible H37Rv
strain, the MIC value of KAN is 1.25 µg/mL, whereas in the
KAN-resistant K204 strain, the MIC value of KAN is 10
µg/mL. As expected, compounds that did not inhibit purified
Mtb Eis (35e, 37d, 87b, 89b, 112b, 115i, 116i, and 139b, e,
and i) did not overcome resistance to KAN in Mtb K204. 28
of the remaining 30 Eis inhibitors resulted in at least a 2-fold
reduction in KAN MIC against Mtb K204, with two of these
compounds, 3i and l lc, lowering KAN MIC 8-fold, down to
the level of the KAN-susceptible H37Rv strain. Not unexpectedly, among very potent inhibitors of the enzymatic
activity of Eis in vitro, there were some compounds that had
little or no effect at sensitizing the resistant Mtb strain K204
to KAN. The compounds that reduced the MIC value of the
KAN-resistant Mtb strain 4-fold had IC 50 values that ranged
from 0.102±0.034 to 3.23±0.99 µM, emphasizing the notion
that in vitro and in cellulo or in vivo activities need not be
perfectly correlated.
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Crystal Structures of Eis-Inhibitor Complexes Reveal the
Inhibition Mechanism.
To elucidate the mechanism of Eis inhibition by the
sulfonyl isothiazole-containing compounds, rationalize the
observed SAR, and guide future rational inhibitor design,
2.2 A-resolution crystal structures of Eis in complex with
CoA and inhibitors 13g and l le (FIGS. 4a,c) were determined, which displayed both potent inhibition of Eis acetylation in vitro and the KAN resistance abolishing effect in
the Mtb cultures. Both inhibitors and their chemical features
were clearly distinguishable and modeled into strong F O -F c
electron density (FIG. 4b,d). The only exception was the
1,2,3,4-tetrahydroisoquinoline (THQ) group of l le, for
which only partial electron density was observed (FIG. 4d),
likely due to a somewhat dynamic behavior of this highly
hydrophobic group in a partially polar environment, as
allowed by the flexible diamine linkage. No other significant
difference electron density that could be attributed to a
bound inhibitor was observed elsewhere. Both inhibitors
exhibited high steric complementarity with the Eis surface.
The binding site for both inhibitors overlapped with the
aminoglycoside substrate-binding site, as was recently
established by the structure ofMtb Eis in complex with CoA
and tobramycin. In addition, the R 2 groups of both inhibitors
reached the C-terminal carboxyl group of Eis, which was
proposed to serve as the general base in the acetyl transfer
reaction. Therefore, these crystal structures indicate that the
inhibitors block access of aminoglycosides to the active site
of the enzyme. Explaining the critical role of the sulfonyl
isothiazole core, this group is bound in the same location and
orientation in both Eis-inhibitor structures (FIG. 4b,d).
Remarkably, despite the nearly identical positions of this
group, there are differences in how this group interacts with
the protein for the two inhibitors. These differences are due
to significant induced-fit conformational changes in the
region spanning residues 26-31 of Eis (FIG. 4b,d), which
uniquely adapts to bind the two structurally different R 2
groups. For inhibitor 13g (FIG. 4a,b), one of the sulfonyl
oxygens forms a direct hydrogen bond with the main chain
amide nitrogen of Phe84 and the ring nitrogen forms a
water-mediated hydrogen bond with the main chain amide
nitrogen of Ile28. In this case, the Eis conformation
resembles that observed in a previously reported crystal
structure with the aminoglycoside-binding pocket unoccupied. Inhibitor Ile does not make any water-mediated contacts due to a small positional shift of the inhibitor and a
conformational change of Eis. Instead, the two sulfonyl
oxygens are at a distance of -4 A, consistent with the
stabilizing van der Waals and electrostatic interactions. The
isothiazole ring is sterically sandwiched between the side
chains of Ile28 and Ser83 in one direction and between the
side chains of Phe24 and Trp36 in the orthogonal direction.
The R 1 groups of the two compounds are almost coplanar
and fit neatly into a nearly fully nonpolar environment of
side chains Leu63, Trp13, and Ala33, the aliphatic stem of
Arg37, Met65, and Phe84, explaining the nonpolar phenyl
ring with small substitutions as effective R 1 groups (Table
5). Such environment, devoid of hydrogen bond donors or
acceptors is appropriate for accommodating halogen substituents, as is the case with Ile and 13g. The halogens can
be accommodated in the para and/or one, but not both meta
positions. Substitutions at both meta positions would not be
accommodated, as reflected in the list of potent inhibitors
(FIG. 3, Table 5), since one of them would clash sterically
with the side chain of Met65. In contrast with R 1 , the
conformations of the R 2 groups of the two inhibitors are
drastically different with one exception-the positively

charged ring nitrogen of R 2 occupies nearly the same location where it forms a salt bridge with the carboxyl group of
Glu401 in both structures. Besides this interaction, R 2 group
of compound 13g makes steric and weak electrostatic interactions with His119, Ser121, Glu401, and the C-terminal
carboxyl group (weakly electrostatically interacting with the
stem N) on one side and making water-mediated steric
interactions with region 26-31 on the other side. In contrast,
for the R 2 of the compound l le: while the interactions with
one face of this group are made with the same amino acid
residues, the other face interacts directly through hydrophobic and steric interactions with the region 26-31, which is in
a different conformation. Most prominently, the side chain
of Asp26 is flipped to interact with the stem, and Phe24
orthogonally stacks against the double ring. Because the R 1
group abuts the hydrophobic wall, whereas R 2 group points
towards the more extended end of the substrate binding
channel, there is more variability in both the identity and the
size of R 2 substituents, as exhibited in the list of effective R 2
groups (Table 4).
Discussion
While it has been met with initial skepticism, target-based
rational drug design is now gaining momentum and is
widely used in industrial and academic drug discovery
pipelines, due to advances in HTS technology, robust assay
development practices and availability of large and diverse
chemical libraries. Prominent examples of successful rational drug design are HIV protease inhibitors ritonavir and the
anticancer drug Gleevec. Here, we report the discovery and
initial preclinical development of novel first-in-class sulfonyl isothiazole inhibitors of a unique acetyltransferase Eis
from Mtb as an agent that overcomes one mechanism of
resistance to KAN in Mtb. Among the diverse pool of
compounds tested, we found agents that we validated as
potent inhibitors of Eis both in the test tube and in the
relevant Mtb cultures. Potencies in mid-nM range appear to
be achieved through binding of the compounds via steric
complementarity, hydrophobic and hydrogen bonding interactions. While one substituent group (R 1 ) is relatively
unchangeable in terms of its size and physico-chemical
properties, the other group (R2 ) can greatly vary. The crystal
structures of Eis-inhibitor complexes demonstrate that binding to variable structures is achieved by conformational
plasticity of the aminoglycoside-binding site of Eis, which
adapts to different R 2 groups, while the R 1 group achieves a
nearly rigid-body fit. Binding of the two inhibitors of Eis
investigated structurally differs not only in protein conformation, but also in the presence or absence of watermediated contacts.
Aminoglycosides are among the antibiotics of last resort
for MDR and XDR-TB patients, and resistance to them
strongly decreases the chances of a favorable treatment
outcome. The strategy of using KAN in combination with an
Eis inhibitor is meant not only to overcome KAN resistance
due to Eis upregulation, but also to curb emergence of new
resistant strains by mutagenesis of the eis promoter, as such
mutation would not have survival benefit in the face of
combination therapy. This study not only validates AAC' s as
drug targets, but has set an important precedent for HTSdriven discovery for AACs that cause resistance in clinically
useful non-TB pathogens, such as AAC(3) and AAC(6') in
Klebsiella pneumoniae (32-34). As with TB, such inhibitory
agents could play an important role in both overcoming
existing resistance and curbing the acquisition of resistance.
In conclusion, we identified potent inhibitors of Eis enzymatic activity with resulting sensitization of KAN-resistant
Mtb cells, in which the resistance to KAN is caused by Eis
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upregulation. The inhibitors bind in the AG binding pocket
blocking the access of AGs to the active site of the enzyme.
The inhibitor binding is accompanied by induced-fit conformational changes of the protein. These compounds have
a great potential for further development as KAN adjuvants
in Mtb.
Protocols:
Detailed versions of the abbreviated protocols below are
provided in the Materials and Methods.
Protein, Reagents, and Small-Molecule Libraries.
The wild-type Eis from Mtb (4), EisC204A (10), AAC
(6')/APH(2") (35), AAC(3)-IV (35), and AAC(2')-Ic (4)
were overexpressed and purified as previously reported,
with minor modifications. All reagents were purchased from
Sigma with the exception of Albumin-dextrose-catalase
(ADC), which was from BD Biosciences. Eis was screened
at the Center for Chemical Genomics (CCG, University of
Michigan) against 123,000 compounds from three libraries.
Compounds were retested as fresh powder samples purchased from ChemDiv.
Eis Chemical Library Screening and Hit Validation.
Screening of small-molecule libraries, hit validation, and
dose response analysis (represented by FIG. 5) were performed as previously described.
Inhibitor Selectivity.
Compounds 46b and 46c were tested against three additional AAC enzymes: AAC(6')/APH(2"), AAC(3)-IV, and
AAC(2')-Ic at optimal reaction conditions for each enzyme.
Mycobacterial MIC Determination by Alamar Blue
Assay.
The assay was done with Mtb strains H37Rv and K204 in
7H9 broth. Compounds were tested at either lOOx IC 50 (if
known) or 20 µM for their inhibitory effect on Mtb growth
and on KAN MIC in these two strains.
Crystallization, Diffraction Data Collection, and Structure
Determination and Refinement of EisC204A-CoA-Inhibitor
Complexes.
Crystals were grown by the hanging drop method and
then underwent a complex harvesting process. The cryoprotectant solution contained 0.5 mM inhibitor. The diffraction
data were collected at synchrotron beamline 22-ID of the
Advanced Photon Source at the Argonne National Laboratory (Argonne, Ill.) at 100 K. The data were processed and
the structures were built and refined by previously described
methods.
Material and Methods

1.2. Synthesis and Characterization of Sulfonamides Generated in this Study.

Example 1
1. Chemistry
1.1. General.
All reagents were purchased from commercial sources
and used without purification. TLC analyses were performed
on silica gel plates (pre-coated on aluminum; 0.20 mm
thickness with fluorescent indicator UV254) and were visualized by UV or charring in KMn04 stains. 1 Hand 13 C NMR
spectra were collected on 400 MHz NMR spectrometer
(VARIAN INOVA) using (CD 3 ) 2 SO. Chemical shifts are
reported in parts per million (ppm) and are referenced to
residual solvent peaks. All reactions were conducted under
nitrogen atmosphere and all yields reported refer to isolated
yields. The known compound A was characterized by 1 H
NMR and is in complete agreement with sample reported
elsewhere. All new compounds were characterized by 1 H,
13
C NMR, and mass spectrometry.
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Synthesis of Compound A.
The known compound A was prepared following a previously published protocol. 1 Chlorosulfonic acid (20.53 mL,
308.36 mmol) was added to quinoxaline-2,3-diol (5.00 g,
30.83 mmol). The reaction mixture was then refluxed for 12
h. After cooling to room temperature, the reaction mixture
was carefully poured onto ice, filtered, and the precipitate
was washed with H 2 0 (50 mL). The solid was collected and
recrystallized with toluene to afford A (7 .07 g, 88%) as a
white solid: 1 H NMR (400 MHz, (CD 3 ) 2 SO, which matches
lit.) ll 11.97 (s, lH), 11.94 (s, lH), 7.43 (d, l=l.6 Hz, lH),
7.30 (dd, 1=8.4, 1.6 Hz, lH), 7.04 (d, 1=8.4 Hz, lH).
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General Procedure for the Synthesis of Sulfonamides
(e.g., Preparation of Compound 29).
A solution of compound A (0.30 g, 1.15 mmol) and
4-bromo-N-methylaniline (0.29 mL, 2.30 mmol) in DMF (6
mL) was stirred at room temperature for 12 h. H 2 0 was
added to the reaction mixture and the formed precipitate was
filtered and washed with H 2 0 (10 mL) to yield 29 (0.21 g,
45%) as a purple solid: 1 H NMR (400 MHz, (CD 3 ) 2 SO) Ii
12.27 (s, lH), 12.00 (s, lH), 7.55 (app dt, 1=9.6, 3.2 Hz, 2H),
7.25 (d, 1=9.6 Hz, 2H), 7.24 (s, lH), 7.07 (app dt, 1=9.2, 3.2
Hz, 2H), 3.09 (s, 3H); 13 C NMR (100 MHz, (CD 3 ) 2 SO) Ii
155.2, 154.8, 140.4, 131.9, 129.8, 129.3, 128.4, 125.9,
122.4, 120.2, 115.5, 114.4, 37.7; LRMS rn/z calcd for
C 15 H 13 BrN3 0 4 S [M+Ht: 410.0; found 410.8.
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Preparation of Compound 30.
As described for the synthesis of compound 29, compound A (0.30 g, 1.15 mmol), 4-bromoaniline (0.39 g, 2.30
mmol), and DMF (6 mL) were used to afford compound 30
(0.21 g, 47%) as a light yellow solid: 1 H NMR (400 MHz,
(CD 3 ) 2 SO) Ii 12.17 (s, lH), 12.09 (s, lH), 10.49 (br s, lH),
7.51 (d, l=l.6 Hz, lH), 7.45 (dd, 1=8.0, 1.6 Hz, lH), 7.41
(app dt, 1=9.6, 2.8 Hz, 2H), 7.19 (d, 1=8.0 Hz, lH), 7.04 (app
dt, 1=9.6, 2.8 Hz, 2H); 13 C NMR (100 MHz, (CD 3 ) 2 SO) Ii
155.2, 154.9, 137.1, 133.1, 132.1, 129.5, 125.9, 121.9,
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121.5, 116.2, 115.6, 113.7, 113.6; LRMS m/z calcd for
C 14H 11 N 3 0 4 SBr [M+Ht: 396.0; found 396.8.

125.9, 122.3, 120.0, 115.4, 114.5, 114.4, 38.0; LRMS m/z
calcd for C 15 H 14N 3 0 4 S [M+Ht: 332.1; found 332.8.
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Preparation of Compound 31.
As described for the synthesis of compound 29, compoundA (0.30 g, 1.15 mmol), aniline (0.21 mL, 2.30 mmol),
and DMF (6 mL) were used to afford compound 31 (0.22 g,
61 % ) as a light yellow solid: 1 H NMR (400 MHz,
(CD 3 ) 2 SO) ll 12.15 (s, lH), 12.08 (s, lH), 10.32 (br s, lH),
7.53 (s, lH), 7.44 (d, J=8.4 Hz, lH), 7.24-7.17 (m, 3H), 7.08
(d, J=8.4 Hz, 2H), 7.02 (t, J=7.2 Hz, lH); 13 C NMR (100
MHz, (CD 3 ) 2 SO) ll 155.2, 154.9, 137.6, 133.5, 129.3, 129.2,
125.8, 124.0, 121.5, 119.9, 115.5, 113.7; LRMS m/z calcd
for C 14H 12N 3 0 4 S [M+Ht: 318.1; found 318.8.
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Preparation of Compound 34.
As described for the synthesis of compound 29, compound A (0.30 g, 1.15 mmol), 4-chloro-N-methylaniline
(0.28 mL, 2.30 mmol), and DMF (6 mL) were used to afford
compound 34 (0.16 g, 38%) as a white solid: 1 H NMR (400
MHz, (CD 3 ) 2 SO) Ii 12.26 (s, lH), 12.00 (s, lH), 7.42 (d,
J=8.8 Hz, 2H), 7.24 (d, J=8.8 Hz, 2H), 7.23 (s, lH), 7.12 (m,
2H), 3.09 (s, 3H); 13 C NMR (100 MHz, (CD 3 ) 2 SO) ll 155.2,
154.8, 140.0, 131.7, 129.8, 129.3, 128.9, 128.6, 128.1,
125.9, 122.4, 115.5, 114.5, 37.8; LRMS m/z calcd for
C 15 H 13 ClN3 0 4 S [M+Ht: 366.0; found 366.8.

25

0

N
H

/~'CC~Xo
II
O

I

#

N
H

0

30

/~'CC~Xo

I aII I

N

O

#

N
H

O

35

Preparation of Compound 32.
As described for the synthesis of compound 29, compound A (0.30 g, 1.15 mmol), 4-isopropylaniline (0.31 g,
2.30 mmol), and DMF (6 mL) were used to afford compound
32 (0.24 g, 59%) as a pink solid: 1 H NMR (400 MHz,
(CD 3 ) 2 SO) ll 12.15 (s, lH), 12.08 (s, lH), 10.21 (br s, lH),
7.52 (d, J=2.0 Hz, lH), 7.44 (dd, J=8.4, 2.0 Hz, lH), 7.18 (d,
J=8.4 Hz, lH), 7.09 (app dt, J=8.4, 2.0 Hz, 2H), 6.99 (app
dt, J=8.4, 2.0 Hz, 2H), 2.76 (hep., J=6.8 Hz, lH), 1.10 (d,
J=6.8 Hz, 6H); 13 C NMR (100 MHz, (CD 3 ) 2 SO) Ii 155.2,
155.0, 144.1, 135.2, 133.8, 129.3, 127.0, 125.8, 121.5,
120.3, 115.5, 113.75, 113.69, 32.7, 23.8; LRMS m/z calcd
for C 17H 18N 3 0 4 S [M+Ht: 360.1; found 360.8.
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Preparation of Compound 35.
As described for the synthesis of compound 29, compound A (0.30 g, 1.15 mmol), 4-isopropyl-N-methylaniline
(0.34 g, 2.30 mmol), and DMF (6 mL) were used to afford
compound 35 (0.20 g, 48%) as a white solid: 1 H NMR (400
MHz, (CD 3 ) 2 SO) Ii 12.25 (s, lH), 12.00 (s, lH), 7.34 (s,
lH), 7.23 (m, lH), 7.21 (dt, J=8.8, 2.4 Hz, 2H), 7.00 (dt,
J=8.8, 2.4 Hz, 2H), 3.09 (s, 3H), 2.88 (hep., J=7.2 Hz, lH),
1.18 (d, J=7.2 Hz, 6H); 13 C NMR (100 MHz, (CD 3 ) 2 SO) Ii
155.2, 154.8, 147.5, 138.8, 130.2, 129.5, 126.8, 126.4,
125.9, 122.3, 115.5, 114.5, 114.4, 38.2, 33.0, 23.8; LRMS
mlz calcd for C 18H 20N 3 0 4 S [M+Ht: 374.1; found 374.8.
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Preparation of Compound 33.
As described for the synthesis of compound 29, compound A (0.30 g, 1.15 mmol), N-methylaniline (0.25 mL,
2.30 mmol), and DMF (6 mL) were used to afford compound
33 (0.27 g, 71%) as a white solid: 1 H NMR (400 MHz,
(CD 3 ) 2 SO) ll 12.24 (s, lH), 12.00 (s, lH), 7.34 (d, J=8.0 Hz,
2H), 7.31-7.29 (m, 2H), 7.22 (s, lH), 7.20 (d, J=l.6 Hz, lH),
7.10 (m, 2H), 3.12 (s, 3H); 13 C NMR (100 MHz, (CD 3 ) 2 SO)
Ii 155.2, 154.8, 141.1, 129.8, 129.6, 129.0, 127.4, 126.4,
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Preparation of Compound 36.
As described for the synthesis of compound 29, compound A (0.30 g, 1.15 mmol), 2-methoxy-N-methylaniline
(0.31 mL, 2.30 mmol), and DMF (6 mL) were used to afford
compound 36 (0.12 g, 29%) as a white solid: 1 H NMR (400
MHz, (CD 3 ) 2 SO) Ii 12.23 (s, lH), 11.99 (s, lH), 7.40 (d,
1=2.0 Hz, lH), 7.38-7.34 (m, lH), 7.33-7.30 (m, lH), 7.24
(d, J=8.4 Hz, lH), 7.14 (dd, J=8.0, 1.2 Hz, lH), 7.01 (dd,
J=8.0, 1.2 Hz, lH), 6.93 (td, J=7.6, 1.2 Hz, lH), 3.36 (s, 3H),
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3.08 (s, 3H); 13 C NMR (100 MHz, (CD 3 ) 2 SO) Ii 156.2,
155.3, 154.9, 132.9, 131.0, 129.8, 129.2, 128.6, 125.7,
122.2, 120.4, 115.2, 114.2, 112.6, 55.2, 37.7; LRMS m/z
calcd for C 16 H 16 BrN3 0 5 S [M+Ht: 362.1; found 362.8.

MHz, (CD 3 ) 2 SO) Ii 12.23 (s, lH), 11.99 (s, lH), 7.33 (d,
l=l.6 Hz, lH), 7.27-7.22 (m, 3H), 6.88 (m, lH), 6.67-6.65
(m, 2H), 3.70 (s, 3H), 3.11 (s, 3H); 13 C NMR (100 MHz,
(CD 3 ) 2 SO) Ii 159.3, 155.1, 154.8, 142.2, 130.0, 129.60,
129.57, 125.8, 122.3, 118.2, 115.4, 114.4, 112.8, 112.3, 55.2,
38.0; LRMS m/z calcd for C 16 H 16 N 3 0 5 S [M+Ht: 362.1;
found 362.8.
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Preparation of Compound 37.
As described for the synthesis of compound 29, com~N
O
pound A (0.30 g, 1.15 mmol), 3-fluoro-N-methylaniline
H
(0.26 mL, 2.30 mmol), and DMF (6 mL) were used to afford
compound 37 (0.06 g, 15%) as a white solid: 1 H NMR (400
20
Preparation of Compound 40.
MHz, (CD 3 ) 2 SO) Ii 12.26 (s, lH), 12.00 (s, lH), 7.39 (app
As
described for the synthesis of compound 29, comq, 1=8.0 Hz, lH), 7.30 (s, lH), 7.23 (m, 2H), 7.16 (td, 1=8.8,
pound A (0.20 g, 0.77 mmol), 3,5-dimethoxy-N-methylani5.6 Hz, lH), 7.03 (dt, 1=10.8, 2.4 Hz, lH), 6.99 (m, lH),
line (0.26 g, 1.54 mmol), and DMF (4 mL) were used to
3.12 (s, 3H); 13 C NMR (100 MHz, (CD 3 ) 2 SO) Ii 163.0,
1
160.6, 155.2, 154.8, 142.8, 142.7, 130.5, 130.4, 129.8, 25 afford compound 40 (0.03 g, 10%) as a white solid: H NMR
)
(400
MHz,
(CD
SO)
012.23
(s,
lH),
12.00
(s,
lH),
7.37 (d,
3 2
129.4, 125.9, 122.3, 122.09, 122.06, 115.5, 114.4, 114.2,
1=2.0
Hz,
lH),
7.29
(dd,
1=8.0,
2.0
Hz,
lH),
7.23
(d,
1=8.0
114.0, 113.4, 113.1, 37.7; LRMS m/z calcd for
Hz, lH), 6.45 (t, 1=2.0 Hz, lH), 6.25 (d, 1=2.0 Hz, 2H), 3.67
C 15 H 13 FN3 0 4 S [M+Ht: 350.1; found 350.8.
(s, 3H), 3.65 (s, 3H), 3.09 (s, 3H); 13 C NMR (100 MHz,
30 (CD 3 ) 2 SO) Ii 160.2, 155.2, 154.8, 142.8, 130.1, 129.6,
125.8, 122.3, 115.4, 114.4, 104.6, 99.1, 55.3, 38.0; LRMS
Br
O
m/z calcd for C 17H 18N 3 0 6 S [M+Ht: 392.1; found 392.8.
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Preparation of Compound 38.
As described for the synthesis of compound 29, compound A (0.30 g, 1.15 mmol), 3-bromo-N-methylaniline
(0.29 mL, 2.30 mmol), and DMF (6 mL) were used to afford
compound 38 (0.02 g, 4%) as a white solid: 1 H NMR (400
MHz, (CD 3 ) 2 SO) ll 12.27 (s, lH), 12.01 (s, lH), 7.51 (ddd,
1=7.6, 2.0, 1.2 Hz, lH), 7.35 (t, 1=2.0 Hz, lH), 7.32 (d, 1=8.0
Hz, lH), 7.29 (m, lH), 7.23 (m, 2H), 7.14 (ddd, 1=7.6, 2.0,
1.2 Hz, lH), 3.11 (s, 3H); 13 C NMR (100 MHz, (CD 3 ) 2 SO)
Ii 155.2, 154.8, 142.6, 130.8, 129.8, 129.3, 129.1, 129.0,
125.9, 125.1, 122.3, 121.3, 115.5, 114.5, 37.7; LRMS m/z
calcd for C 15 H 13 BrN3 0 4 S [M+Ht: 410.0; found 410.8.
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Preparation of Compound 41.
As described for the synthesis of compound 29, compound A (0.20 g, 0.77 mmol), 3-methyl-N-methylaniline
(0.19 mL, 1.54 mmol), and DMF (4 mL) were used to afford
compound 41 (0.15 g, 58%) as a white solid: 1 H NMR (400
MHz, (CD 3 ) 2 SO) Ii 12.23 (s, lH), 11.98 (s, lH), 7.32 (m,
lH), 7.24-7.20 (m, 3H), 7.11 (m, lH), 6.96 (m, lH), 6.85 (m,
lH), 3.09 (s, 3H), 2.27 (s, 3H); 13 C NMR (100 MHz,
(CD 3 ) 2 SO) Ii 155.2, 154.8, 141.1, 138.3, 130.0, 129.5,
128.7, 128.0, 127.1, 125.8, 123.2, 122.3, 115.4, 114.4, 38.0,
20.8; LRMS m/z calcd for C 16 H 16 N 3 0 4 S [M+Ht: 346.1;
found 346.8.

55

/~u~xo
0

60

I aII I

N

#

Preparation of Compound 39.
As described for the synthesis of compound 29, compound A (0.20 g, 0.77 mmol), 3-methoxy-N-methylaniline
(0.20 mL, 1.54 mmol), and DMF (4 mL) were used to afford
compound 39 (0.05 g, 17%) as a gray solid: 1 H NMR (400
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Preparation of Compound 42.
As described for the synthesis of compound 29, compoundA (0.20 g, 0.77 mmol), 3-ethyl-N-methylaniline (0.21
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g, 1.54 mmol), and DMF (4 mL) were used to afford
compound 42 (0.20 g, 74%) as a white solid: 1H NMR (400
MHz, (CD 3)2SO) ll 12.23 (s, lH), 11.98 (s, lH), 7.30 (s, lH),
7.25 (t, 1=8.8, lH), 7.23 (s, lH), 7.14 (d, 1=7.2 Hz, lH), 6.89
(m, 2H), 3.10 (s, 3H), 2.55 (q, 1=8.0 Hz, 2H), 1.09 (t, 1=8.0
Hz, 3H); 13 C NMR (100 MHz, (CD 3) 2SO) Ii 155.1, 154.8,
144.6, 141.1, 129.9, 129.5, 128.8, 126.9, 125.8, 123.7,
122.3, 115.4. 114.5, 38.1, 27.9, 15.4; LRMS m/z calcd for
C 17H 18N 30 4 S [M+Ht: 360.1; found 360.8.

Preparation of Compound 45.
As described for the synthesis of compound 29, compound A (0.03 g, 0.13 mmol), 3-t-butyl-N-methylaniline
(0.04 g, 0.27 mmol), and DMF (1 mL) were used to afford
compound 45 (0.03 g, 58%) as a brown solid: 1H NMR (400
MHz, (CD 3)2SO) Ii 12.25 (s, lH), 11.99 (s, lH), 7.32 (dt,
1=8.0, 1.6 Hz, lH), 7.30-7.26 (m, 2H), 7.23 (m, 2H), 6.94 (t,
l=l.6 Hz, lH), 6.92 (d, l=l.6 Hz, lH), 3.11 (s, 3H), 1.17 (s,
9H); 13 C NMR (100 MHz, (CD3)2SO) ll 155.1, 154.7, 151.5,
140.9, 129.9, 129.5, 128.6, 125.7, 124.3, 124.0, 123.3,
122.3, 115.4, 114.6, 38.2, 34.3, 30.8; LRMS m/z calcd for
C 19 H 21 N 30 4 S [M+Ht: 387.1; found 387.8.
Preparation of Compound 46.
As described for the synthesis of compound 29, compound A (0.20 g, 0.77 mmol), N-methyl-2-naphthylamine
(0.24 g, 1.54 mmol), and DMF (4 mL) were used to afford
compound 46 (0.16 g, 55%) as an orange solid: 1H NMR
(400 MHz, (CD 3)2SO) Ii 12.24 (s, lH), 11.95 (s, lH),
7.95-7.86 (m, 3H), 7.64 (d, 1=2.0 Hz, lH), 7.52 (m, 2H),
7.31-7.29 (m, 2H), 7.23 (m, 2H), 3.22 (s, 3H); 13 C NMR
(100 MHz, (CD 3)2SO) Ii 155.1, 154.8, 138.6, 132.9, 131.7,
129.8, 129.6, 128.5, 127.9, 127.5, 126.6, 126.4, 125.9,
124.9, 124.3, 122.4, 115.5, 114.4, 38.1; LRMS m/z calcd for
C 19 H 15 N 30 4 S [M+Ht: 381.1; found 381.8.
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Preparation of Compound 43.
As described for the synthesis of compound 29, compound A (0.07 g, 0.27 mmol), 3-i-propyl-N-methylaniline
(0.08 g, 0.54 mmol), and DMF (1.5 mL) were used to afford
compound 43 (0.06 g, 60%) as a white solid: 1H NMR (400
MHz, (CD 3)2SO) Ii 12.25 (s, lH), 11.99 (s, lH), 7.27 (d,
1=8.0 Hz, lH), 7.26 (t, 1=8.0 Hz, lH), 7.22 (d, 1=2.0 Hz,
lH), 7.21 (dd, 1=8.4, 1.6 Hz, lH), 7.17 (dt, 1=8.0, 1.2 Hz,
lH), 6.92 (ddd, 1=8.0, 2.0, 1.2 Hz, lH), 6.85 (t, 1=2.0 Hz,
lH), 3.10 (s, 3H), 2.81 (hep., 1=6.8 Hz, lH), 1.10 (d, 1=6.8
Hz, 6H); 13 C NMR (100 MHz, (CD 3) 2SO) Ii 155.2, 154.8,
149.3, 141.1, 129.9, 129.5, 128.8, 125.8, 125.5, 124.3,
124.2, 122.3, 115.4, 114.6, 38.1, 33.1, 23.6; LRMS m/z
calcd for C 18 H 19 N 30 4 S [M+Ht: 373.1; found 373.8.
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Preparation of Compound 44.
As described for the synthesis of compound 29, compoundA (0.06 g, 0.25 mmol), 3-butyl-N-methylaniline (0.08
g, 0.49 mmol), and DMF (1.5 mL) were used to afford
compound 44 (0.10 g, 100%) as a pink solid: 1H NMR (400
MHz, (CD 3)2SO) Ii 12.26 (s, lH), 11.98 (s, lH), 7.27 (m,
lH), 7.25 (s, lH), 7.22 (m, 2H), 7.11 (d, 1=8.0 Hz, lH), 6.94
(m, lH), 6.80 (t, 1=2.0 Hz, lH), 3.11 (s, 3H), 1.42-1.37 (m,
3H), 1.24-1.17 (m, 3H), 0.82 (t, 1=7 .6 Hz, 3H); 13 C NMR
(100 MHz, (CD 3)2SO) Ii 155.2, 154.8, 143.2, 141.0, 129.9,
129.5, 128.7, 127.4, 125.9, 125.8, 124.1, 122.3, 115.4,
114.6, 38.1, 34.5, 33.0, 21.6, 13.8; LRMS m/z calcd for
C 18H 19N 30 4 S [M+Ht: 373.1; found 373.8.
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Preparation of Compound 47.
As described for the synthesis of compound 29, compoundA (0.09 g, 0.35 mmol), N-methyl-4-methoxy-2-naphthylamine (0.13 g, 0.70 mmol), and DMF (2 mL) were used
to afford compound 47 (0.03 g, 21 % ) as a yellow solid: 1H
NMR (400 MHz, (CD 3)2SO) ll 12.24 (s, lH), 11.97 (s, lH),
8.11-8.09 (m, lH), 7.82-7.80 (m, lH), 7.55-7.48 (m, 2H),
7.35 (d, 1=2.0 Hz, lH), 7.31 (dd, 1=8.4, 2.0 Hz, lH), 7.23 (d,
1=8.4 Hz, lH), 7.20 (d, l=l.2 Hz, lH), 6.71 (d, 1=2.0 Hz,
lH), 3.87 (s, 3H), 3.21 (s, 3H); 13 C NMR (100 MHz,
(CD 3)2SO) Ii 155.2, 154.9, 154.8, 139.1, 133.4, 129.9,
129.7, 127.8, 127.2, 125.9, 125.8, 123.7, 122.5, 121.3,
116.7, 115.4, 114.5, 103.9, 55.7, 38.2; LRMS m/z calcd for
C 20 H 17N 30 5S [M+Ht: 411.1; found 411.8.
2. Biochemistry and Biology:
2.1. Protein, Reagents, and Small-Molecule Libraries.
Recombinant Mtb Eis protein (Eis_Mtb ), AAC( 6')-Ie/
APH(2")-Ia, AAC(3)-IV, and AAC(2')-Ic were expressed
and purified as reported previously. All chemicals including
5',5-dithiobis-(2-nitrobenzoic acid) (DTNB), Tween® 80,
neomycin B (NEO), kanamycin A (KAN), acetyl-CoA (AcCoA), and chlorhexidine were purchased from Sigma-Aldrich (St. Louis, Mo., USA). Albumin-dextrose-catalase
(ADC) was from BD Biosciences (San Jose, Calif., USA).
The high-throughput screening (HTS) to identify inhibitors
of the acetyltransferase activity of purified Eis_Mtb was
carried out at the Center for Chemical Genomics (CCG,
University of Michigan) against 123,000 compounds from
(i) a ChemDiv library (120,000), (ii) the BioFocus NCC
library, and (iii) the MicroSource MS2000 library. All small
molecules were dissolved in DMSO prior to testing. The
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immediate follow-up assays to confirm inhibition or triage
in 50 mL polypropylene tubes containing glass beads and
false positives were performed with hit compounds from
vortexed for 30 sec. The cultures were kept still for 10 min,
fresh powders purchased from ChemDiv (San Diego, Calif.,
and then 90 µL aliquots were distributed into the wells of a
USA). Note: All concentrations noted below are the final
clear 96-well culture plate. Compounds were initially tested
concentrations in the assays.
5 at concentrations that were either 100-fold higher than their
2.2. Eis Chemical Library Screening.
IC 50 KAN or at 100 µM if the IC 50 ,KAN value was unknown
HTS was performed as previously described. 4 Briefly,
or c~uld not be achieved while keeping the DMSO concentrations 1% in test wells. Working stocks for each compound
absorbance signal from the reaction of the enzymatically
released CoASH with Ellman's reagent, DTNB, at 412 nm
were prepared at concentrations twice that of the desired
1
1
(E 412 =14150 M- cm- ) was used to monitor the acetylation 1o final concentration in fresh 7H9 medium, and 100 µL of each
by Eis_Mtb. The reactions (40 µL) contained Tris (50 mM,
of these working stocks was added to the 90 µL of bacterial
cultures in the wells. The plates were incubated at 37° C. for
pH 8.0 adjusted at room temperature), Eis (0.25 µM), NEO
24 h in a humid environment before the addition of KAN (10
(100 µM), AcCoA (40 µM), DTNB (0.5 mM), and library
compounds (20 µM). Chlorhexidine (5 µM) and DMSO
µL). Growth ofH37Rv was evaluated at 2.5, and 1.25 µg/mL
(0.5%) served as positive and negative controls, respec- 15 KAN while growth ofK204 was evaluated at 10, 5, 2.5, and
tively. Plates were incubated at room temperature and read
1.25 µg/mL KAN. The plates were incubated at 37° C. for
6 days after the addition of KAN. Then, 40 µL of alamar blue
on a PHERAstar plate reader at 5 min after initiation of the
diluted 1:2 in 10% Tween® 80 was added to each well and
reaction. The average Z' score for the HTS assay was 0.60.
2.3. Hit Validation.
the plates continued to be incubated 3 7° C. The color of each
Hit compounds were defined as displaying 3-fold or 20 well was preliminarily evaluated 24 h after the addition of
stronger inhibition than the standard deviation (calculated
alamar blue, with a final evaluation after 48 h. Alamar blue
for the inert compounds) in the HTS. These compounds
changes from indigo blue to pink as a result of bacterial
were tested in triplicate. The compounds that exhibited
growth. The lowest concentration of KAN that resulted in no
reproducible inhibitory activity in two out of three trials
change in color was defined as the MIC for each concenwere then tested in dose-response assays in the concentra- 25 tration of an inhibitory compound. Compound screening
tion range from 20 µM to 78 nM (generated by 2-fold
was carried out on biological replicates in duplicate. Several
dilutions of the compound stock), and IC 50 values were
controls were included with every compound: uninoculated
obtained for all compounds displaying dose-dependent inhi7H9, compound and inoculated 7H9 only, inoculated 7H9+
bition.
DMSO only, and inoculated 7H9 only. For each plate, 2004
2.4. Inhibition Kinetics.
30 of sterile water was added to all perimeter wells to minimize
Absorbance was measured on a SpectraMax MS plate
evaporation.
3. Structural Biology:
reader, for the reaction mixtures in 96-well plates (Thermo
3.1. Purification of EisC204A.
Fisher Scientific). Measurements were taken every 30 s for
10 min. Compounds were first serially dissolved in Tris-HCl
The active point mutant EisC204A that is less prone to
(50 mM, pH 8.0, containing 10% v/v DMSO). A mixture (50 35 oxidation than the wild-type Eis_Mtb was overexpressed in
BL21(DE3) E.coli and purified as previously reported, with
µL) of Eis (1 µM), KAN (400 µM), and Tris-HCl (50 mM,
only minor modifications, as follows. The EisC204ApH 8.0) was added to the inhibitors and incubated for 10
pET28a plasmid was transformed into E. coli BL21 (DE3)
min. Reactions were initiated by the addition of a mixture
(50 µL) ofDTNB (8 mM), AcCoA (2 mM), and Tris-HCl (50
chemically competent cells and plated onto LB agar conmM, pH 8.0). All assays were performed in triplicate. IC 50 40 taining kanamycin (KAN; 50 µg/mL). After overnight incubation, a single colony from the plate was inoculated into LB
values were calculated by curved fitting to a Hill plot with
broth (5 mL) containing KAN (50 µg/mL) (LB/KAN). This
KaleidaGraph 3.6 software (Table 2 and FIG. 1).
culture was grown at 37° C. until the attenuance at 600 nm
2.5. Inhibitor Selectivity.
To investigate the selectivity of our inhibitors towards Eis,
of 0.5, then the culture was inoculated into 4 L of LB/KAN
compounds 39 and 46 were tested against three additional 45 and grown at 37° C.At the attenuance at 600 nm of-0.1, the
culture was transferred to 16° C. for 1.5 h, and then IPTG
AAC enzymes: AAC(2')-Ic, AAC(3)-IV, and AAC(6')-Ie/
APH(2")-Ia. The conditions utilized for determination of
was added at the final concentration of0.5 mM. The induced
culture was grown for an additional 16-18 hat 16° C. with
IC 50 values were also used here under the optimum condishaking (200 rpm). All following purification steps were
tions for each enzyme. Compounds 39 and 46 (200 to 100
pM) were dissolved in buffer (50 mM MES pH 6.6 for 50 done at 4 ° C. The cells were pelleted by centrifugation at
5,000 rpm for 10 min. The cell pellets were resuspended in
AAC(6')-Ie/APH(2")-Ia and AAC(3)-IV and 100 mM
chilled lysis buffer (NaCl (300 mM), Tris-HCl pH 8.0
sodium phosphate pH 7.4 for AAC(2')-Ic). Enzyme (0.25
adjusted at room temperature (40 mM), glycerol (10% v/v),
µM for AAC(6')-Ie/APH(2")-Ia, 0.125 µM for AAC(3)-IV
and ~-mercaptoethanol (2 mM)). The cells were then disand AAC(2')-Ic), NEO (100 µM), and AcCoA (150 µM)
were used for these assays. AAC(3)-IV and AAC(2')-Ic 55 rupted by sonication and the insoluble material was removed
by centrifugation at 35,000xg for 45 min at 4° C. The
experiments were incubated at 25° C. AAC(6')-Ie/APH(2")Ia experiments were incubated at 37° C. All other methods
supernatant was passed through a 0.45 µm Millex-HV PVDF
and concentrations are the same as for the experiments with
filter (Millipore, Billerica, Mass., USA) and then loaded
Eis_Mtb.
onto a 5 mL Ni-IMAC HisTrap FF column (GE Healthcare)
2.6. Mycobacterial MIC Determination by Alamar Blue 60 pre-equilibrated in the lysis buffer. The column was washed
with 100 mL oflysis buffer containing 20 mM imidazole and
Assay.
then the protein was eluted in 10 mL of lysis buffer conMtb strains H37Rv and K204 were inoculated from
taining 200 mM imidazole. The eluate was concentrated
frozen stocks into Middlebrook 7H9 broth supplemented
using anAmicon Ultra-15 (10,000 MWCO) centrifugal filter
with ADC (10%), Tween® 80 (0.05%), and glycerol (0.4%),
and incubated at 37° C. until turbidity appeared. The cul- 65 device (Millipore) to the volume of 5 mL. The protein was
then purified on a size-exclusion S-200 column (GE Healthtures were diluted with fresh 7H9 medium to the attenuance
at 600 nm of 0.2, further diluted 1:25 in fresh 7H9 medium
care) equilibrated in gel filtration buffer (Tris-HCl pH 8.0
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(40 mM), NaCl (100 mM), and ~-mercaptoethanol (2 mM)).
The Eis-containing fractions were pooled and concentrated
using an Amicon Ultra (10,000 MWCO) centrifugal filter
device (Millipore) to 4 mg/mL. The pure Eis protein was
stored on ice at 4 ° C.
3.2. Crystallization, Diffraction Data Collection, and
Structure Determination and Refinement of EisC204ACoA-Inhibitor 39 Complex.
Crystals were grown by vapor diffusion in hanging drops
containing 14 of concentrated (4 mg/mL) EisC204A protein
containing KAN (10 mM), and CoA (8 mM) mixed with 1
µL of the reservoir solution (Tris-HCI pH 8.5 adjusted at
room temperature (100 mM), PEG 8,000 (10-15% w/v), and
(NH4 ) 2 S04 (0.4 M)). The drops were equilibrated against 1
mL of the reservoir solution at 22° C. Single crystals were
obtained in 2-3 weeks. The crystals were first gradually
transferred into the reservoir solution. The (NH4 ) 2 S04 and
KAN were then exchanged out of the solvent by a gradual
transfer into the reservoir solution lacking (NH4 ) 2 S04 :
(Tris-HCI pH 8.5 (100 mM) and PEG 8,000 (13% w/v)).
Then the crystals were gradually transferred into the cryoprotectant solution (Tris-HCI pH 8.5 (100 mM), PEG 8,000
(13% w/v), and glycerol (20% v/v)) and incubated in this
solution for 10 min. Upon the incubation, the crystals were
transferred in the inhibitor solution (the cryoprotectant solution containing 0.5 mM inhibitor) for 30 min, and then
frozen in liquid nitrogen by quick immersion.
The X-ray diffraction data were collected at 100 K at
synchrotron beamline 22-ID of the Advanced Photon Source
at the Argonne National Laboratory (Argonne, Ill.). The data
were processed with HKL2000. The crystal form was the
same as that of wild-type Eis-CoA-acetamide complex
determined previously by our group (PDB code 3R1K) and
contained one Eis monomer in the asymmetric unit, with the
Eis hexamer generated by crystal symmetry operations. This
crystal structure (without ligands or water molecules) was
used as the starting point, and rigid body refinement was
performed by Refmac, with the Eis monomer as a single
rigid-body domain. After the rigid body refinement, strong
difference F O -F c electron density for the inhibitor 39 mo!ecule and a part of CoA was apparent, which allowed
building of the molecules into the difference electron density
with Coot program. The structures of EisC204A-CoA-inhibitor 39 complex was iteratively built and refined using
programs Coot and Refmac, respectively. The data collection and refinement statistics for the structures reported here
are given in Table 3. The EisC204A-CoA-inhibitor complex
structures have been deposited in the Protein Data Bank. The
accession number is 5EBV for the crystal structure of
acetyltransferase Eis from Mycobacterium tuberculosis in
complex with inhibitor l lc and CoA; and the accession
number is 5EC4 for the crystal structure of acetyltransferase
Eis from Mycobacterium tuberculosis in complex with
inhibitor 13g and CoA.

Genomics (CCG, University of Michigan) against 123,000
compounds from (i) a ChemDiv library (120,000), (ii) the
BioFocus NCC library, and (iii) the MicroSource MS2000
library. All small molecule stock solutions for HTS were
prepared in DMSO. The activity of promising compounds
was confirmed using fresh powder samples purchased from
ChemDiv (San Diego, Calif., USA). Note: All concentrations noted below are final concentration.
Eis Chemical Library Screening.
Screening of small-molecule libraries was performed as
previously described. (3) Briefly, a UV-Vis assay monitoring
the reaction of the enzymatically released CoASH with
Ellman's reagent, DTNB, at 412 nm (E 412 =14150 M- 1 cm- 1 )
was used to determine inhibition of Eis. The final reactions
(40 µL) contained Tris (50 mM, pH 8.0 adjusted at room
temperature), Eis (0.25 µM), NEO (100 µM), AcCoA (40
µM), DTNB (0.5 mM), and molecules from the HTS libraries (20 µM). Chlorhexidine (5 µM) and DMSO (0.5%) were
used as positive and negative controls, respectively. Plates
were incubated at room temperature and read on a
PHERAstar plate reader at a single end point reading at 5
min after initiation of the reaction. The average Z' score for
the entire high-throughput screening assay was 0.60.
Hit Validation.
Compound from the initial screen determined to be hits
(>3a, statistically above the negative control) were tested in
triplicate. All compounds inhibiting Eis in two out of three
trials were then tested in a dose-dependent manner using
two-fold dilutions from 20 µM to 78 nM, and IC 50 values
were determined for all compounds having dose-dependent
activity.
Inhibition Kinetics.
All IC 50 values were determined by UV-Vis assays monitoring CoASH release (see Eis chemical library screening
above) by using a Multimode SpectraMax MS plate reader
in 96-well plates. Reactions (200 µL) contained inhibitors
(200 µM to 2 pM), Tris (50 mM, pH 8.0 adjusted at room
temperature), Eis (0.25 µM), AcCoA (500 µM), KAN (100
µM), and DTNB (2 mM). To calculate IC 50 values, a Hill
plot fit was generated with KaleidaGraph 4.1 software by
using the initial rates (first 2-5 min ofreactions) normalized
to reactions where inhibitors were omitted. IC 50 values are
presented in Table 7 and representative dose-response
curves are displayed in FIG. 5.
Inhibitor Selectivity.
Compounds 46b and 46c were tested against three additional AAC enzymes: AAC(6')/APH(2"), AAC(3)-IV, and
AAC(2')-Ic. The conditions described above for determination of IC 50 values were used under the optimum conditions
for each enzyme. Compounds 46b and 46c (200 µM to 100
pM) were dissolved in buffer (50 mM MES pH 6.6 for
AAC(6')/APH(2") and AAC(3)-IV and 75 mM sodium
phosphate pH 7.4 for AAC(2')-Ic). Enzyme (0.25 µM for
AAC(6')/APH(2"), 125 nM for AAC(3)-IV andAAC(2')-Ic),
NEO (100 µM), and AcCoA (150 µM) were used for these
tests. AAC(6')/APH(2") experiments were incubated at 37°
C. while AAC(3)-IV and AAC(2')-Ic experiments were
incubated at 25° C. All other methods and concentrations
remained identical to those for the experiments with Eis.
Mycobacterial MIC Determination by Alamar Blue
Assay.
Mtb strains H37Rv and K204 were inoculated from
frozen stocks into Middlebrook 7H9 broth supplemented
with ADC (10%), Tween® 80 (0.05%), and glycerol (0.4%),
and incubated at 37° C. until turbid. Cultures were diluted to
an A 600 of 0.2 in fresh 7H9 medium, then additionally
diluted 1:25 in 7H9 medium in 50 mL polypropylene tubes
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Example 2
Protein, Reagents, and Small-Molecule Libraries.
The Eis from Mtb, (1) AAC(6')/APH(2"), (2) AAC(3)-IV,
(2) and AAC(2')-Ic(l) were overexpressed and purified as
previously reported in the literature. All reagents including
5',5-dithiobis-(2-nitrobenzoic acid) (DTNB), Tween® 80,
neomycin B (NEO), kanamycin A (KAN), acetyl-CoA (AcCoA), and chlorhexidine were purchased from Sigma-Aldrich (St. Louis, Mo., USA). Albumin-dextrose-catalase
(ADC) was purchased from BD Biosciences (San Jose,
Calif., USA). Eis was screened at the Center for Chemical
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containing glass beads, vortexed for 30 sec, allowed to settle
for 10 min, and 90 µL was distributed into wells of a clear
96-well culture plate. Compounds were tested at either lOOx
their IC 50 (if known) or 20 µM. Working stocks for each
compound were prepared at 2x their desired final test
concentration in fresh 7H9 medium, and 100 µL of 2x
working stocks was added to test wells containing 90 µL of
bacteria. Plates were incubated at 37° C. for 24 h in a humid
environment before the addition of KAN (10 µL ). Growth of
H37Rv was evaluated at 5, 2.5, 1.25, 0.625, 0.312 and 0.156
µg/mL KAN while growth of K204 was evaluated at 20, 10,
5, 2.5, 1.25, 0.625 µg/mL KAN. Plates were incubated at 37°
C. for 6 days after the addition of KAN. Then, 40 µL of
alamar blue diluted 1:2 in 10% Tween® 80 was added to
each well and plates were returned to 37° C. The color of
each well was preliminarily evaluated 24 h after the addition
of alamar blue, with a final evaluation after 48 h. Alamar
blue changes from indigo blue to pink as a result of bacterial
growth. The lowest concentration of KAN that resulted in no
color change was recorded as the MIC for each concentration of compound. Compound screening was done on biological replicates in triplicate. Several controls were evaluated with every compound including, uninoculated 7H9,
compound+inoculated 7H9 only, inoculated 7H9+DMSO
only, and inoculated 7H9 only. For each plate, 200 µL of
sterile ddH 2 0 was added to all perimeter wells to prevent
evaporation.
Purification of EisC204A.
EisC204A was expressed and purified as described, (4)
with minor modifications, as follows. The EisC204ApET28a construct was transformed into E. coli BL21 (DE3)
chemically competent cells, plated onto LB agar containing
kanamycin (KAN; 50 µg/mL). A colony from the transformation plate was inoculated into LB broth (5 mL) supplemented with KAN (50 µg/mL) (LB/KAN) and the culture
was grown at 37° C. until mid-log phase. This 5-mL culture
was then inoculated into 4 L of LB/KAN and grown at 37°
C. When attenuance at 600 nmreached-0.1, the culture was
transferred to 16° C. for -1.5 h, and then IPTG was added
at the final concentration of 0.5 mM. The induced culture
was grown for an additional 16-18 hat 16° C. (Note: All
culture growth steps were performed with shaking at 200
rpm. All purification steps were carried out at 4° C.). The
cells were harvested by centrifugation at 5,000 rpm for 10
min at 4 ° C. The cell pellets were resuspended in lysis buffer
(NaCl (300 mM), Tris-HCl pH 8.0 adjusted at room ternperature (40 mM), glycerol (10% v/v), and ~-mercaptoethanol (2 mM)). The cells were disrupted by sonication on ice
and the insoluble cell debris were removed by centrifugation
at 35,000xg for 45 min at 4 ° C. The supernatant was filtered
through a 0.45 µm Millex-HV PVDF filter (Millipore,
Billerica, Mass., USA) and applied to a 5 mL Ni-IMAC
HisTrap FF colunm (GE Healthcare) equilibrated with lysis
buffer. The protein was then eluted with lysis buffer in a

stepwise imidazole gradient (6x5 mL fractions of 10 mM
imidazole, 6x5 mL fractions of 20 mM imidazole, 3x5 mL
fractions of 50 mM imidazole, and 7x5 mL fractions of 250
mM imidazole). The eluted fractions containing more than
95% pure desired protein, as determined by SDS-PAGE,
were pooled and concentrated using an Amicon Ultra-15
(5,000 MWCO) centrifugal filter device (Millipore). The
protein was further purified on a size-exclusion S-200 colunm (GE Healthcare) equilibrated in gel filtration buffer
(Tris-HCl pH 8.0 (40 mM), NaCl (100 mM), and ~-mercaptoethanol (2 mM)), and the Eis-containing fractions were
pooled and concentrated using an Amicon Ultra (5,000
MWCO) centrifugal filter device (Millipore) to 4 mg/mL.
The pure Eis protein was stored at 4 ° C.
Crystallization, Diffraction Data Collection, and Structure
Determination and Refinement of EisC204A-CoA-Inhibitor
Complexes.
Crystals were grown by vapor diffusion in hanging drops
containing 1 µL of concentrated (4 mg/mL) EisC204A
protein, KAN (10 mM), and CoA (8 mM) mixed with 1 µIL
of the reservoir solution (Tris-HCl pH 8.5 adjusted at room
temperature (100 mM), PEG 8,000 (10-15% w/v), and
(NH4 ) 2 S04 (0.4 M)) equilibrated against 1 mL of the reservoir solution at 22° C. Single crystals were obtained in 2-3
weeks. The crystals were first gradually transferred into the
reservoir solution. The (NH4 ) 2 S04 and KAN were
exchanged out of the crystals by a gradual transfer into the
reservoir solution lacking (NH4 ) 2 S04 (Tris-HCl pH 8.5 (100
mM) and PEG 8,000 (13% w/v)). CoA remained stably
bound to Eis during this procedure. Then the crystals were
gradually transferred into the cryoprotectant solution (TrisHCl pH 8.5 (100 mM), PEG 8,000 (13% w/v), and glycerol
(20% v/v)). After this transfer, the crystals were soaked in
the inhibitor solution (the cryoprotectant solution containing
0.5 mM inhibitor) for 30 min, then rapidly frozen in liquid
nitrogen.
The diffraction data were collected at synchrotron beamline 22-ID of the Advanced Photon Source at the Argonne
National Laboratory (Argonne, Ill.) at 100 K. The data were
indexed, integrated and scaled with HKL2000. The crystal
form coincided with that of wild-type Eis-CoA-acetamide
complex determined previously by our group (PDB code
3R1K(l )). The Eis from this structure was the starting point,
and performed rigid body refinement by Refmac. After rigid
body refinement, strong difference F O -F c electron density for
an inhibitor molecule and a part of CoA was apparent, which
allowed facile building of these molecules by using Coot.
The structures of EisC204A-CoA-inhibitor complexes were
iteratively built and refined using programs Coot and Refmac, respectively. The data collection and refinement statistics for the structures reported here are given in Table 8.
The EisC204A-CoA-inhibitor Ile and 13g structures were
deposited in the Protein Data Bank with the PDB accession
numbers 5EBV and 5EC4, respectively.
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TABLE 8
X-ray diffraction data collection and refinement statistics for the
EisC204A-CoA-inhibitor llc and EisC204A-CoA-inhibitor 13g ternary
complex structures.
Data collection
Space group
Number of monomers per asymmetric Wlit
Unit cell dimensions
a, b, c (A)
a, b, g (*)
Resolution (A)
Ifs

llc
R32
1

13g
R32
1

175.2, 175.2, 122.3
90, 90, 120
50.0-2.2 (2.24-2.20)"
21 (2.9)

175.6, 175.6, 122.2
90, 90, 120
50.0-2.2 (2.24-2.20)"
24 (4.0)
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TABLE 8-continued
X-ray diffraction data collection and refinement statistics for the
EisC204A-CoA-inhibitor 11c and EisC204A-CoA-inhibitor 13g ternary
complex structures.
Completeness (%)
Redundancy
Rmerge

Number of unique reflections
Structure refinement statistics
Resolution (A)
R(%)
Rfree (%)
Bond lengtb deviation (rmsd) from ideal
(A)
Bond angle deviation (rmsd) from ideal ( 0 )
Ramachandran plot statisticsb
%
%
%
%

of residues
of residues
of residues
of residues

in
in
in
in

most allowed regions
additional allowed regions
generously allowed regions
disallowed regions

99.9 (100)
9.5 (9.4)
0.11 (0.62)
34,661

40.0-2.2
19.4
21.5
0.006

99.8 (99.4)
7.3 (7.3)
0.10 (0.56)
34,541

40.0-2.2
20.0
23.8
0.007

1.34

1.46

94.1
5.9
0.0
0.0 (0 residues)

93.2
6.8
0.0
0.0 (0 residues)

"Numbers in parentheses indicate the values in the highest-resolution shell.
bindicates Procheck statistics. (8)
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2. A pharmaceutical composition comprising the compound of claim 1, and a suitable pharmaceutical carrier.

3. The composition of claim 2, and further comprising an
aminoglycoside.

R2 is selected from:
35

4. The composition of claim 3, wherein the aminoglycoside is kanamycin (KAN).
5. A method of inhibiting Eis comprising administering to
a subject an effective amount of a composition comprising
a compound according to the formula
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or a compound of claim 1.
6. A method of inhibiting Eis comprising administering an
effective amount of a composition comprising a compound
according to the formula:
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7. d1:he method of claim 6, wherein the compound is
accor mg to the formula:

50

55

wherein Rl is
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and R2 is -NH(CH 2 ) 3 N(CH 2 CH 3 ) 2 ; Rl is

8. The method claim 5, wherein a MICKAN value is less

than about 0.625 µg/mL for Mycobacterium tuberculosis
(Mtb) strain H37Rv or less than about 5 µg/mL for Mtb
strain K204.

~

9. The method of claim 5, further comprising administering an aminoglycoside.
10. The method of claim 9, wherein the aminoglycoside
is kanamycin (KAN).

Cl

and R2 is

10

15

11. A method of treating aminoglycoside-resistant Mycobacterium tuberculosis (Mtb ), comprising administering the
compound of claim 1 to a subject.
12. The method of claim 11, further comprising administering an aminoglycoside.
13. The method of claim 12, wherein the aminoglycoside
is kanamycin (KAN).

or Rl is
20

14. The method of claim 12, wherein the aminoglycoside
is administered to a subject in need of treatment for aminoglycoside-resistant Mtb.
15. A kit comprising the compound of claim 1, packaged
together with an aminoglycoside.
16. The kit of claim 15, wherein the aminoglycoside is
kanamycin (KAN).
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